WO2022103927A1 - Immunogenic compositions for coronaviruses - Google Patents
Immunogenic compositions for coronaviruses Download PDFInfo
- Publication number
- WO2022103927A1 WO2022103927A1 PCT/US2021/058920 US2021058920W WO2022103927A1 WO 2022103927 A1 WO2022103927 A1 WO 2022103927A1 US 2021058920 W US2021058920 W US 2021058920W WO 2022103927 A1 WO2022103927 A1 WO 2022103927A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- lipoprotein
- certain embodiments
- coronavirus
- subject
- immunogenic composition
- Prior art date
Links
- 241000711573 Coronaviridae Species 0.000 title claims abstract description 100
- 230000002163 immunogen Effects 0.000 title claims description 93
- 239000000203 mixture Substances 0.000 title claims description 92
- 108090001030 Lipoproteins Proteins 0.000 claims abstract description 179
- 102000004895 Lipoproteins Human genes 0.000 claims abstract description 179
- 239000000427 antigen Substances 0.000 claims abstract description 96
- 102000036639 antigens Human genes 0.000 claims abstract description 96
- 108091007433 antigens Proteins 0.000 claims abstract description 96
- 108010028921 Lipopeptides Proteins 0.000 claims abstract description 45
- 238000000034 method Methods 0.000 claims abstract description 29
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 63
- 235000001014 amino acid Nutrition 0.000 claims description 56
- 150000002632 lipids Chemical group 0.000 claims description 56
- 241001678559 COVID-19 virus Species 0.000 claims description 37
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 29
- -1 E6020 Chemical compound 0.000 claims description 16
- 230000003053 immunization Effects 0.000 claims description 16
- 238000000746 purification Methods 0.000 claims description 15
- 230000036039 immunity Effects 0.000 claims description 14
- 230000001681 protective effect Effects 0.000 claims description 14
- 101000629318 Severe acute respiratory syndrome coronavirus 2 Spike glycoprotein Proteins 0.000 claims description 13
- 239000002671 adjuvant Substances 0.000 claims description 13
- 241000315672 SARS coronavirus Species 0.000 claims description 12
- 208000001528 Coronaviridae Infections Diseases 0.000 claims description 11
- 230000028993 immune response Effects 0.000 claims description 11
- 238000003776 cleavage reaction Methods 0.000 claims description 8
- 229940035032 monophosphoryl lipid a Drugs 0.000 claims description 8
- 230000007017 scission Effects 0.000 claims description 8
- MTCFGRXMJLQNBG-UHFFFAOYSA-N serine Chemical compound OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 claims description 8
- 108091005804 Peptidases Proteins 0.000 claims description 7
- 239000004365 Protease Substances 0.000 claims description 7
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 claims description 6
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 claims description 6
- 239000000556 agonist Substances 0.000 claims description 6
- OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical compound NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 claims description 6
- 125000001165 hydrophobic group Chemical group 0.000 claims description 6
- 238000006467 substitution reaction Methods 0.000 claims description 6
- 244000309467 Human Coronavirus Species 0.000 claims description 5
- 206010061598 Immunodeficiency Diseases 0.000 claims description 5
- 241000127282 Middle East respiratory syndrome-related coronavirus Species 0.000 claims description 5
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 5
- 210000003719 b-lymphocyte Anatomy 0.000 claims description 5
- 230000015572 biosynthetic process Effects 0.000 claims description 5
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 claims description 5
- 208000024891 symptom Diseases 0.000 claims description 5
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 claims description 5
- RHKWIGHJGOEUSM-UHFFFAOYSA-N 3h-imidazo[4,5-h]quinoline Chemical class C1=CN=C2C(N=CN3)=C3C=CC2=C1 RHKWIGHJGOEUSM-UHFFFAOYSA-N 0.000 claims description 4
- 108010042708 Acetylmuramyl-Alanyl-Isoglutamine Proteins 0.000 claims description 4
- 201000003176 Severe Acute Respiratory Syndrome Diseases 0.000 claims description 4
- 108010055044 Tetanus Toxin Proteins 0.000 claims description 4
- 229940037003 alum Drugs 0.000 claims description 4
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 claims description 4
- ILRRQNADMUWWFW-UHFFFAOYSA-K aluminium phosphate Chemical compound O1[Al]2OP1(=O)O2 ILRRQNADMUWWFW-UHFFFAOYSA-K 0.000 claims description 4
- 150000003857 carboxamides Chemical class 0.000 claims description 4
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 claims description 4
- 210000002443 helper t lymphocyte Anatomy 0.000 claims description 4
- DOUYETYNHWVLEO-UHFFFAOYSA-N imiquimod Chemical compound C1=CC=CC2=C3N(CC(C)C)C=NC3=C(N)N=C21 DOUYETYNHWVLEO-UHFFFAOYSA-N 0.000 claims description 4
- 229960002751 imiquimod Drugs 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims description 4
- 229940118376 tetanus toxin Drugs 0.000 claims description 4
- YYGNTYWPHWGJRM-UHFFFAOYSA-N (6E,10E,14E,18E)-2,6,10,15,19,23-hexamethyltetracosa-2,6,10,14,18,22-hexaene Chemical compound CC(C)=CCCC(C)=CCCC(C)=CCCC=C(C)CCC=C(C)CCC=C(C)C YYGNTYWPHWGJRM-UHFFFAOYSA-N 0.000 claims description 3
- AGBQKNBQESQNJD-ZETCQYMHSA-N (S)-lipoic acid Chemical compound OC(=O)CCCC[C@H]1CCSS1 AGBQKNBQESQNJD-ZETCQYMHSA-N 0.000 claims description 3
- XRILCFTWUCUKJR-INFSMZHSSA-N 2'-3'-cGAMP Chemical compound C([C@H]([C@H]1O)O2)OP(O)(=O)O[C@H]3[C@@H](O)[C@H](N4C5=NC=NC(N)=C5N=C4)O[C@@H]3COP(O)(=O)O[C@H]1[C@@H]2N1C=NC2=C1NC(N)=NC2=O XRILCFTWUCUKJR-INFSMZHSSA-N 0.000 claims description 3
- ZOOGRGPOEVQQDX-UUOKFMHZSA-N 3',5'-cyclic GMP Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=C(NC2=O)N)=C2N=C1 ZOOGRGPOEVQQDX-UUOKFMHZSA-N 0.000 claims description 3
- 241000004176 Alphacoronavirus Species 0.000 claims description 3
- 241000008904 Betacoronavirus Species 0.000 claims description 3
- 108010061994 Coronavirus Spike Glycoprotein Proteins 0.000 claims description 3
- 102000016607 Diphtheria Toxin Human genes 0.000 claims description 3
- 108010053187 Diphtheria Toxin Proteins 0.000 claims description 3
- 108090001126 Furin Proteins 0.000 claims description 3
- JZNWSCPGTDBMEW-UHFFFAOYSA-N Glycerophosphorylethanolamin Natural products NCCOP(O)(=O)OCC(O)CO JZNWSCPGTDBMEW-UHFFFAOYSA-N 0.000 claims description 3
- 201000005505 Measles Diseases 0.000 claims description 3
- 108091036414 Polyinosinic:polycytidylic acid Proteins 0.000 claims description 3
- 241001522306 Serinus serinus Species 0.000 claims description 3
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 claims description 3
- BHEOSNUKNHRBNM-UHFFFAOYSA-N Tetramethylsqualene Natural products CC(=C)C(C)CCC(=C)C(C)CCC(C)=CCCC=C(C)CCC(C)C(=C)CCC(C)C(C)=C BHEOSNUKNHRBNM-UHFFFAOYSA-N 0.000 claims description 3
- 229940123384 Toll-like receptor (TLR) agonist Drugs 0.000 claims description 3
- LUXUAZKGQZPOBZ-SAXJAHGMSA-N [(3S,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl] (Z)-octadec-9-enoate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC1O[C@H](CO)[C@@H](O)[C@H](O)[C@@H]1O LUXUAZKGQZPOBZ-SAXJAHGMSA-N 0.000 claims description 3
- GUIRUWRHBDQCQJ-UHFFFAOYSA-N [(6-oxo-1,7-dihydropurin-2-yl)amino]phosphonic acid Chemical compound P(=O)(O)(O)NC=1NC(C=2NC=NC=2N=1)=O GUIRUWRHBDQCQJ-UHFFFAOYSA-N 0.000 claims description 3
- 229910052782 aluminium Inorganic materials 0.000 claims description 3
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 claims description 3
- 229940047712 aluminum hydroxyphosphate Drugs 0.000 claims description 3
- 229940104302 cytosine Drugs 0.000 claims description 3
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N dodecahydrosqualene Natural products CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 claims description 3
- VZCCETWTMQHEPK-QNEBEIHSSA-N gamma-linolenic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/CCCCC(O)=O VZCCETWTMQHEPK-QNEBEIHSSA-N 0.000 claims description 3
- 208000002672 hepatitis B Diseases 0.000 claims description 3
- 206010022000 influenza Diseases 0.000 claims description 3
- GZQKNULLWNGMCW-PWQABINMSA-N lipid A (E. coli) Chemical compound O1[C@H](CO)[C@@H](OP(O)(O)=O)[C@H](OC(=O)C[C@@H](CCCCCCCCCCC)OC(=O)CCCCCCCCCCCCC)[C@@H](NC(=O)C[C@@H](CCCCCCCCCCC)OC(=O)CCCCCCCCCCC)[C@@H]1OC[C@@H]1[C@@H](O)[C@H](OC(=O)C[C@H](O)CCCCCCCCCCC)[C@@H](NC(=O)C[C@H](O)CCCCCCCCCCC)[C@@H](OP(O)(O)=O)O1 GZQKNULLWNGMCW-PWQABINMSA-N 0.000 claims description 3
- 238000012986 modification Methods 0.000 claims description 3
- 230000004048 modification Effects 0.000 claims description 3
- BSOQXXWZTUDTEL-ZUYCGGNHSA-N muramyl dipeptide Chemical compound OC(=O)CC[C@H](C(N)=O)NC(=O)[C@H](C)NC(=O)[C@@H](C)O[C@H]1[C@H](O)[C@@H](CO)O[C@@H](O)[C@@H]1NC(C)=O BSOQXXWZTUDTEL-ZUYCGGNHSA-N 0.000 claims description 3
- RRTPWQXEERTRRK-UHFFFAOYSA-N n-[4-(4-amino-2-butylimidazo[4,5-c]quinolin-1-yl)oxybutyl]octadecanamide Chemical compound C1=CC=CC2=C3N(OCCCCNC(=O)CCCCCCCCCCCCCCCCC)C(CCCC)=NC3=C(N)N=C21 RRTPWQXEERTRRK-UHFFFAOYSA-N 0.000 claims description 3
- 150000008104 phosphatidylethanolamines Chemical class 0.000 claims description 3
- 229940115272 polyinosinic:polycytidylic acid Drugs 0.000 claims description 3
- GRLPQNLYRHEGIJ-UHFFFAOYSA-J potassium aluminium sulfate Chemical compound [Al+3].[K+].[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O GRLPQNLYRHEGIJ-UHFFFAOYSA-J 0.000 claims description 3
- BXNMTOQRYBFHNZ-UHFFFAOYSA-N resiquimod Chemical compound C1=CC=CC2=C(N(C(COCC)=N3)CC(C)(C)O)C3=C(N)N=C21 BXNMTOQRYBFHNZ-UHFFFAOYSA-N 0.000 claims description 3
- 229940031439 squalene Drugs 0.000 claims description 3
- TUHBEKDERLKLEC-UHFFFAOYSA-N squalene Natural products CC(=CCCC(=CCCC(=CCCC=C(/C)CCC=C(/C)CC=C(C)C)C)C)C TUHBEKDERLKLEC-UHFFFAOYSA-N 0.000 claims description 3
- YYGNTYWPHWGJRM-AAJYLUCBSA-N squalene Chemical compound CC(C)=CCC\C(C)=C\CC\C(C)=C\CC\C=C(/C)CC\C=C(/C)CCC=C(C)C YYGNTYWPHWGJRM-AAJYLUCBSA-N 0.000 claims description 3
- SLKDGVPOSSLUAI-PGUFJCEWSA-N 1,2-dihexadecanoyl-sn-glycero-3-phosphoethanolamine zwitterion Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OCCN)OC(=O)CCCCCCCCCCCCCCC SLKDGVPOSSLUAI-PGUFJCEWSA-N 0.000 claims description 2
- 241000494545 Cordyline virus 2 Species 0.000 claims description 2
- 102000004961 Furin Human genes 0.000 claims description 2
- 102000002689 Toll-like receptor Human genes 0.000 claims description 2
- 108020000411 Toll-like receptor Proteins 0.000 claims description 2
- 230000001419 dependent effect Effects 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 abstract description 2
- 125000003473 lipid group Chemical group 0.000 abstract 1
- 229940024606 amino acid Drugs 0.000 description 51
- 150000001413 amino acids Chemical class 0.000 description 46
- 125000005647 linker group Chemical group 0.000 description 38
- 229960005486 vaccine Drugs 0.000 description 23
- 230000002209 hydrophobic effect Effects 0.000 description 18
- 125000001183 hydrocarbyl group Chemical group 0.000 description 14
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 11
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 11
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 11
- 108010076504 Protein Sorting Signals Proteins 0.000 description 10
- 238000002649 immunization Methods 0.000 description 10
- 102000004196 processed proteins & peptides Human genes 0.000 description 10
- UPAQRWMRKQCLSD-HTIIIDOHSA-N 2,3-dipalmitoyl-S-glycerylcysteine Chemical compound CCCCCCCCCCCCCCCC(=O)OCC(CSC[C@H](N)C(O)=O)OC(=O)CCCCCCCCCCCCCCC UPAQRWMRKQCLSD-HTIIIDOHSA-N 0.000 description 9
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 9
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 9
- 108010084333 N-palmitoyl-S-(2,3-bis(palmitoyloxy)propyl)cysteinyl-seryl-lysyl-lysyl-lysyl-lysine Proteins 0.000 description 9
- 125000000539 amino acid group Chemical group 0.000 description 9
- 229910052739 hydrogen Inorganic materials 0.000 description 9
- 239000001257 hydrogen Substances 0.000 description 9
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 9
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 8
- 208000025721 COVID-19 Diseases 0.000 description 8
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 8
- 208000025370 Middle East respiratory syndrome Diseases 0.000 description 8
- 108010038122 S-(2,3-bis(palmitoyloxy)propyl)cysteine Proteins 0.000 description 8
- 125000000217 alkyl group Chemical group 0.000 description 8
- 238000003556 assay Methods 0.000 description 8
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 7
- 235000008206 alpha-amino acids Nutrition 0.000 description 7
- 235000002639 sodium chloride Nutrition 0.000 description 7
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 6
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 6
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 6
- 210000004369 blood Anatomy 0.000 description 6
- 239000008280 blood Substances 0.000 description 6
- 210000004899 c-terminal region Anatomy 0.000 description 6
- 125000004432 carbon atom Chemical group C* 0.000 description 6
- 235000013922 glutamic acid Nutrition 0.000 description 6
- 239000004220 glutamic acid Substances 0.000 description 6
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 5
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 5
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 5
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 5
- 239000004472 Lysine Substances 0.000 description 5
- 208000035415 Reinfection Diseases 0.000 description 5
- 125000003118 aryl group Chemical group 0.000 description 5
- 235000003704 aspartic acid Nutrition 0.000 description 5
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 5
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 5
- 150000002148 esters Chemical group 0.000 description 5
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 5
- 235000018977 lysine Nutrition 0.000 description 5
- 238000006386 neutralization reaction Methods 0.000 description 5
- 230000003362 replicative effect Effects 0.000 description 5
- 150000003839 salts Chemical class 0.000 description 5
- 150000003568 thioethers Chemical group 0.000 description 5
- 239000013603 viral vector Substances 0.000 description 5
- 125000003088 (fluoren-9-ylmethoxy)carbonyl group Chemical group 0.000 description 4
- 229940096437 Protein S Drugs 0.000 description 4
- 208000037847 SARS-CoV-2-infection Diseases 0.000 description 4
- 101710198474 Spike protein Proteins 0.000 description 4
- 150000001298 alcohols Chemical class 0.000 description 4
- 125000003342 alkenyl group Chemical group 0.000 description 4
- 150000001370 alpha-amino acid derivatives Chemical class 0.000 description 4
- 125000000129 anionic group Chemical group 0.000 description 4
- 235000013877 carbamide Nutrition 0.000 description 4
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 150000002170 ethers Chemical group 0.000 description 4
- 238000004128 high performance liquid chromatography Methods 0.000 description 4
- 230000002401 inhibitory effect Effects 0.000 description 4
- 230000005764 inhibitory process Effects 0.000 description 4
- 230000003472 neutralizing effect Effects 0.000 description 4
- 229910052757 nitrogen Inorganic materials 0.000 description 4
- 229910052760 oxygen Inorganic materials 0.000 description 4
- 238000010647 peptide synthesis reaction Methods 0.000 description 4
- 150000003904 phospholipids Chemical class 0.000 description 4
- 150000003140 primary amides Chemical class 0.000 description 4
- 150000003141 primary amines Chemical class 0.000 description 4
- 229920005989 resin Polymers 0.000 description 4
- 239000011347 resin Substances 0.000 description 4
- 150000003334 secondary amides Chemical class 0.000 description 4
- 150000003335 secondary amines Chemical class 0.000 description 4
- 239000007790 solid phase Substances 0.000 description 4
- 150000003511 tertiary amides Chemical group 0.000 description 4
- 150000003512 tertiary amines Chemical group 0.000 description 4
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 3
- QNAYBMKLOCPYGJ-UWTATZPHSA-N D-alanine Chemical compound C[C@@H](N)C(O)=O QNAYBMKLOCPYGJ-UWTATZPHSA-N 0.000 description 3
- 238000002965 ELISA Methods 0.000 description 3
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical group OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 3
- 239000004471 Glycine Substances 0.000 description 3
- AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- AHLPHDHHMVZTML-UHFFFAOYSA-N Orn-delta-NH2 Natural products NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 description 3
- UTJLXEIPEHZYQJ-UHFFFAOYSA-N Ornithine Natural products OC(=O)C(C)CCCN UTJLXEIPEHZYQJ-UHFFFAOYSA-N 0.000 description 3
- 101800000905 Spike protein S2 Proteins 0.000 description 3
- 241000700605 Viruses Species 0.000 description 3
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- 150000001371 alpha-amino acids Chemical class 0.000 description 3
- 150000001408 amides Chemical class 0.000 description 3
- 235000009582 asparagine Nutrition 0.000 description 3
- 229960001230 asparagine Drugs 0.000 description 3
- 239000004202 carbamide Substances 0.000 description 3
- 125000002091 cationic group Chemical group 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 235000018417 cysteine Nutrition 0.000 description 3
- 125000000524 functional group Chemical group 0.000 description 3
- 210000004072 lung Anatomy 0.000 description 3
- 239000002105 nanoparticle Substances 0.000 description 3
- 229960003104 ornithine Drugs 0.000 description 3
- 239000002245 particle Substances 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 125000002653 sulfanylmethyl group Chemical group [H]SC([H])([H])[*] 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- 239000004475 Arginine Substances 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 108020004414 DNA Proteins 0.000 description 2
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 2
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 2
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 2
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 2
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 2
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 2
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 2
- 108091028043 Nucleic acid sequence Proteins 0.000 description 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
- 206010035664 Pneumonia Diseases 0.000 description 2
- 102000002067 Protein Subunits Human genes 0.000 description 2
- 108091005634 SARS-CoV-2 receptor-binding domains Proteins 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 2
- 239000004473 Threonine Substances 0.000 description 2
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 2
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 2
- OQEIOUBBMBZINL-UHFFFAOYSA-N [2-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-hexadecanoyloxypropyl] hexadecanoate Chemical compound CCCCCCCCCCCCCCCC(=O)OCC(OP(O)(=O)OCCN)COC(=O)CCCCCCCCCCCCCCC OQEIOUBBMBZINL-UHFFFAOYSA-N 0.000 description 2
- 235000004279 alanine Nutrition 0.000 description 2
- 125000003277 amino group Chemical group 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 229920001400 block copolymer Polymers 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 108700010904 coronavirus proteins Proteins 0.000 description 2
- 230000008878 coupling Effects 0.000 description 2
- 238000010168 coupling process Methods 0.000 description 2
- 238000005859 coupling reaction Methods 0.000 description 2
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 2
- 235000004554 glutamine Nutrition 0.000 description 2
- 125000001072 heteroaryl group Chemical group 0.000 description 2
- 125000000623 heterocyclic group Chemical group 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 238000005342 ion exchange Methods 0.000 description 2
- 229960000310 isoleucine Drugs 0.000 description 2
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 2
- 239000002502 liposome Substances 0.000 description 2
- 238000004949 mass spectrometry Methods 0.000 description 2
- 108020004999 messenger RNA Proteins 0.000 description 2
- 229930182817 methionine Natural products 0.000 description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
- 238000011587 new zealand white rabbit Methods 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- 230000007170 pathology Effects 0.000 description 2
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 2
- 239000013612 plasmid Substances 0.000 description 2
- 125000006239 protecting group Chemical group 0.000 description 2
- 235000018102 proteins Nutrition 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 238000003757 reverse transcription PCR Methods 0.000 description 2
- 238000004007 reversed phase HPLC Methods 0.000 description 2
- 235000004400 serine Nutrition 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 239000012536 storage buffer Substances 0.000 description 2
- 229940031626 subunit vaccine Drugs 0.000 description 2
- 229910052717 sulfur Inorganic materials 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 150000003573 thiols Chemical class 0.000 description 2
- UMGDCJDMYOKAJW-UHFFFAOYSA-N thiourea Chemical compound NC(N)=S UMGDCJDMYOKAJW-UHFFFAOYSA-N 0.000 description 2
- 235000008521 threonine Nutrition 0.000 description 2
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 2
- 229940125575 vaccine candidate Drugs 0.000 description 2
- 239000004474 valine Substances 0.000 description 2
- 230000003612 virological effect Effects 0.000 description 2
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 1
- AKIIJJAKZRNOLW-HTIIIDOHSA-N (2r)-2-[di(hexadecanoyl)amino]-3-(2,3-dihydroxypropylsulfanyl)propanoic acid Chemical compound CCCCCCCCCCCCCCCC(=O)N([C@@H](CSCC(O)CO)C(O)=O)C(=O)CCCCCCCCCCCCCCC AKIIJJAKZRNOLW-HTIIIDOHSA-N 0.000 description 1
- CSMYOORPUGPKAP-IBGZPJMESA-N (2r)-3-(acetamidomethylsulfanyl)-2-(9h-fluoren-9-ylmethoxycarbonylamino)propanoic acid Chemical compound C1=CC=C2C(COC(=O)N[C@@H](CSCNC(=O)C)C(O)=O)C3=CC=CC=C3C2=C1 CSMYOORPUGPKAP-IBGZPJMESA-N 0.000 description 1
- PZFZLRNAOHUQPH-DJBVYZKNSA-N (2r)-3-[(2r)-2,3-di(hexadecanoyloxy)propyl]sulfanyl-2-(hexadecanoylamino)propanoic acid Chemical compound CCCCCCCCCCCCCCCC(=O)N[C@H](C(O)=O)CSC[C@H](OC(=O)CCCCCCCCCCCCCCC)COC(=O)CCCCCCCCCCCCCCC PZFZLRNAOHUQPH-DJBVYZKNSA-N 0.000 description 1
- XSYUPRQVAHJETO-WPMUBMLPSA-N (2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-amino-3-(1h-imidazol-5-yl)propanoyl]amino]-3-(1h-imidazol-5-yl)propanoyl]amino]-3-(1h-imidazol-5-yl)propanoyl]amino]-3-(1h-imidazol-5-yl)propanoyl]amino]-3-(1h-imidazol-5-yl)propanoyl]amino]-3-(1h-imidaz Chemical compound C([C@H](N)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1NC=NC=1)C(O)=O)C1=CN=CN1 XSYUPRQVAHJETO-WPMUBMLPSA-N 0.000 description 1
- SHINASQYHDCLEU-BKLSDQPFSA-N (2s)-4-aminopyrrolidine-2-carboxylic acid Chemical compound NC1CN[C@H](C(O)=O)C1 SHINASQYHDCLEU-BKLSDQPFSA-N 0.000 description 1
- ICGQLNMKJVHCIR-UHFFFAOYSA-N 1,3,2-dioxazetidin-4-one Chemical compound O=C1ONO1 ICGQLNMKJVHCIR-UHFFFAOYSA-N 0.000 description 1
- ATAFDSCDEDHMOK-UHFFFAOYSA-N 3,3-diaminopropanoic acid Chemical compound NC(N)CC(O)=O ATAFDSCDEDHMOK-UHFFFAOYSA-N 0.000 description 1
- OWSRLHPWDZOHCR-UHFFFAOYSA-N 4,4-diaminobutanoic acid Chemical compound NC(N)CCC(O)=O OWSRLHPWDZOHCR-UHFFFAOYSA-N 0.000 description 1
- FZTIWOBQQYPTCJ-UHFFFAOYSA-N 4-[4-(4-carboxyphenyl)phenyl]benzoic acid Chemical compound C1=CC(C(=O)O)=CC=C1C1=CC=C(C=2C=CC(=CC=2)C(O)=O)C=C1 FZTIWOBQQYPTCJ-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
- 208000010470 Ageusia Diseases 0.000 description 1
- 206010002653 Anosmia Diseases 0.000 description 1
- 108010077805 Bacterial Proteins Proteins 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- 102000014914 Carrier Proteins Human genes 0.000 description 1
- 108010078791 Carrier Proteins Proteins 0.000 description 1
- 108020004705 Codon Proteins 0.000 description 1
- 108091035707 Consensus sequence Proteins 0.000 description 1
- 241000314928 Cordyline virus 1 Species 0.000 description 1
- 241000004175 Coronavirinae Species 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 150000008574 D-amino acids Chemical class 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 238000008157 ELISA kit Methods 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 208000018522 Gastrointestinal disease Diseases 0.000 description 1
- 241000204888 Geobacter sp. Species 0.000 description 1
- XYZZKVRWGOWVGO-UHFFFAOYSA-N Glycerol-phosphate Chemical compound OP(O)(O)=O.OCC(O)CO XYZZKVRWGOWVGO-UHFFFAOYSA-N 0.000 description 1
- 102000004457 Granulocyte-Macrophage Colony-Stimulating Factor Human genes 0.000 description 1
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000669447 Homo sapiens Toll-like receptor 4 Proteins 0.000 description 1
- 102000008100 Human Serum Albumin Human genes 0.000 description 1
- 108091006905 Human Serum Albumin Proteins 0.000 description 1
- 241000482741 Human coronavirus NL63 Species 0.000 description 1
- 108010002350 Interleukin-2 Proteins 0.000 description 1
- 150000008575 L-amino acids Chemical class 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- RHGKLRLOHDJJDR-BYPYZUCNSA-N L-citrulline Chemical compound NC(=O)NCCC[C@H]([NH3+])C([O-])=O RHGKLRLOHDJJDR-BYPYZUCNSA-N 0.000 description 1
- FFFHZYDWPBMWHY-VKHMYHEASA-N L-homocysteine Chemical compound OC(=O)[C@@H](N)CCS FFFHZYDWPBMWHY-VKHMYHEASA-N 0.000 description 1
- 125000000510 L-tryptophano group Chemical group [H]C1=C([H])C([H])=C2N([H])C([H])=C(C([H])([H])[C@@]([H])(C(O[H])=O)N([H])[*])C2=C1[H] 0.000 description 1
- 241000713666 Lentivirus Species 0.000 description 1
- 206010024971 Lower respiratory tract infections Diseases 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 101100481584 Mus musculus Tlr1 gene Proteins 0.000 description 1
- 208000000112 Myalgia Diseases 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- RHGKLRLOHDJJDR-UHFFFAOYSA-N Ndelta-carbamoyl-DL-ornithine Natural products OC(=O)C(N)CCCNC(N)=O RHGKLRLOHDJJDR-UHFFFAOYSA-N 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- 206010068319 Oropharyngeal pain Diseases 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 201000007100 Pharyngitis Diseases 0.000 description 1
- 229920001710 Polyorthoester Polymers 0.000 description 1
- 241001112090 Pseudovirus Species 0.000 description 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
- 208000004756 Respiratory Insufficiency Diseases 0.000 description 1
- 208000036071 Rhinorrhea Diseases 0.000 description 1
- 206010039101 Rhinorrhoea Diseases 0.000 description 1
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical class [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 102100039360 Toll-like receptor 4 Human genes 0.000 description 1
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 1
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 1
- 108010067390 Viral Proteins Proteins 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- DHKHKXVYLBGOIT-UHFFFAOYSA-N acetaldehyde Diethyl Acetal Natural products CCOC(C)OCC DHKHKXVYLBGOIT-UHFFFAOYSA-N 0.000 description 1
- 150000001241 acetals Chemical class 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 125000004442 acylamino group Chemical group 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 235000019666 ageusia Nutrition 0.000 description 1
- 125000005529 alkyleneoxy group Chemical group 0.000 description 1
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 1
- 229910021502 aluminium hydroxide Inorganic materials 0.000 description 1
- 229940001007 aluminium phosphate Drugs 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 229910000329 aluminium sulfate Inorganic materials 0.000 description 1
- DIZPMCHEQGEION-UHFFFAOYSA-H aluminium sulfate (anhydrous) Chemical compound [Al+3].[Al+3].[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O DIZPMCHEQGEION-UHFFFAOYSA-H 0.000 description 1
- 235000011128 aluminium sulphate Nutrition 0.000 description 1
- 150000001409 amidines Chemical class 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 125000000637 arginyl group Chemical group N[C@@H](CCCNC(N)=N)C(=O)* 0.000 description 1
- 125000000613 asparagine group Chemical group N[C@@H](CC(N)=O)C(=O)* 0.000 description 1
- 125000004429 atom Chemical group 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000002238 attenuated effect Effects 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 239000004621 biodegradable polymer Substances 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 208000027499 body ache Diseases 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 150000001720 carbohydrates Chemical group 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 235000013477 citrulline Nutrition 0.000 description 1
- 229960002173 citrulline Drugs 0.000 description 1
- 208000027744 congestion Diseases 0.000 description 1
- 239000000562 conjugate Substances 0.000 description 1
- 230000001268 conjugating effect Effects 0.000 description 1
- 230000021615 conjugation Effects 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 230000009260 cross reactivity Effects 0.000 description 1
- 150000001945 cysteines Chemical class 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 239000000412 dendrimer Substances 0.000 description 1
- 229920000736 dendritic polymer Polymers 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 150000001990 dicarboxylic acid derivatives Chemical class 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 208000010643 digestive system disease Diseases 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 241001493065 dsRNA viruses Species 0.000 description 1
- 238000002330 electrospray ionisation mass spectrometry Methods 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 150000002191 fatty alcohols Chemical class 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 208000018685 gastrointestinal system disease Diseases 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 150000002334 glycols Chemical class 0.000 description 1
- 229910052736 halogen Inorganic materials 0.000 description 1
- 150000002367 halogens Chemical group 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 125000005842 heteroatom Chemical group 0.000 description 1
- 150000007857 hydrazones Chemical class 0.000 description 1
- 239000000017 hydrogel Substances 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 1
- 150000003949 imides Chemical class 0.000 description 1
- 150000002466 imines Chemical class 0.000 description 1
- 210000004201 immune sera Anatomy 0.000 description 1
- 229940042743 immune sera Drugs 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 229910021645 metal ion Inorganic materials 0.000 description 1
- 238000002941 microtiter virus yield reduction assay Methods 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 210000004897 n-terminal region Anatomy 0.000 description 1
- 201000009240 nasopharyngitis Diseases 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 150000002482 oligosaccharides Chemical class 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 239000007800 oxidant agent Substances 0.000 description 1
- 150000002923 oximes Chemical class 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 125000001312 palmitoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000000863 peptide conjugate Substances 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 239000000419 plant extract Substances 0.000 description 1
- 229920001983 poloxamer Polymers 0.000 description 1
- 229920000747 poly(lactic acid) Polymers 0.000 description 1
- 229920001610 polycaprolactone Polymers 0.000 description 1
- 229920002721 polycyanoacrylate Polymers 0.000 description 1
- 239000004626 polylactic acid Substances 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920006324 polyoxymethylene Polymers 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 229940068968 polysorbate 80 Drugs 0.000 description 1
- 229910000160 potassium phosphate Inorganic materials 0.000 description 1
- 235000011009 potassium phosphates Nutrition 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 229960000380 propiolactone Drugs 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 201000004193 respiratory failure Diseases 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 208000023504 respiratory system disease Diseases 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 229930182490 saponin Natural products 0.000 description 1
- 150000007949 saponins Chemical class 0.000 description 1
- 235000017709 saponins Nutrition 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 229930195734 saturated hydrocarbon Natural products 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 235000011008 sodium phosphates Nutrition 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- FDDDEECHVMSUSB-UHFFFAOYSA-N sulfanilamide Chemical compound NC1=CC=C(S(N)(=O)=O)C=C1 FDDDEECHVMSUSB-UHFFFAOYSA-N 0.000 description 1
- 229940124530 sulfonamide Drugs 0.000 description 1
- 150000003457 sulfones Chemical class 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 229940021747 therapeutic vaccine Drugs 0.000 description 1
- 150000003585 thioureas Chemical class 0.000 description 1
- 238000004448 titration Methods 0.000 description 1
- 150000003852 triazoles Chemical class 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 150000004043 trisaccharides Chemical class 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- 229930195735 unsaturated hydrocarbon Natural products 0.000 description 1
- 150000003672 ureas Chemical class 0.000 description 1
- 239000000277 virosome Substances 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6018—Lipids, e.g. in lipopeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
- A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/20011—Coronaviridae
- C12N2770/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Definitions
- Coronaviruses are species of viruses belonging to the subfamily Coronavirinae in the family Coronaviridae, and are positive-sense RNA viruses that infect humans and animals and cause respiratory, gastrointestinal or neurologic disease.
- Human coronavrisues include 229E, NL63, OC43, HKU1, MERS-CoV, SARS-CoV, and SARS-CoV-2.
- Common human coronaviruses include OC43, HKU1, 229E, and HCoV-NL63 that cause common colds and more severe lower respiratory tract infections in the very young and the elderly.
- SARS-CoV severe coronavirus
- MERS-CoV MERS-CoV
- SARS-CoV-2 also referred to as COVID-19
- SARS-CoV-2 also referred to as COVID-19
- Synthetic virus-like particles have been utilized for vaccine development. Specifically, SVLP -based vaccine candidates using synthetic lipopeptide building blocks to which antigens are conjugated, which spontaneously self-assemble into immunogenic nanoparticles have been developed (see, WO2015/082501 and WO2020/127728). Additionally, certain SLVPs have been developed that include T-helper epitopes and coiled-coil domains (see, WO2018/229159 and W02008/068017). Despite these recent developments, there is still a need for SVLP -based vaccine candidates, most particularly for treating, preventing, or ameliorating coronaviruses, such as SARS-CoV-2, and diseases, disorders, and conditions related thereto.
- coronaviruses such as SARS-CoV-2
- a lipoprotein comprising (a) a lipopeptide building block comprising: (i) a lipid moiety and (ii) an amphipathic domain; and (b) an antigen of a coronavirus.
- the lipoprotein is a nanomicelle.
- the lipid moiety is a Toll-like receptor (TLR) agonist.
- the TLR agonist is a TLR-2 agonist.
- the lipid moiety has a structure selected from the group consisting of LM1, LM2, LM3, LM4, LM5, LM6, LM7, and LM8.
- the lipid moiety is selected from the group consisting of Cys((R)- 2,3-di(palmitoyloxy)-2-propyl) (Pam2Cys), Cys((R)-2,3-di(palmitoyloxy)-2-propyl-N- palmitoyl) (Pam3Cys), unsaturated Pam3Cys, phosphatidylethanolamine, diphosphoryl hexaacyl lipid A, l,2-dipalmitoyl-sn-glycero-3 -phosphoethanolamine, and 1,3-dipalmitoyl- glycero-2-phosphoethanolamine.
- the amphipathic domain is a coiled-coil domain.
- the coiled-coil domain directs formation of helical bundles.
- the coiled-coil domain comprises a heptad motif, (abcdefg)n, wherein each a and d independently represents a hydrophobic residue and each b, c, e, f, and g independently represents a polar residue.
- the amphipathic domain comprises an amino acid sequence selected from the group consisting of SEQ ID Nos. 1-48.
- the amphipathic domain comprises an amino acid sequence consisting of an amino acid sequence selected from the group consisting of SEQ ID Nos. 1-48.
- the amphipathic domain consists of an amino acid sequence selected from the group consisting of SEQ ID Nos. 1-48.
- the lipoprotein further comprises a T-helper epitope.
- the lipopeptide building block further comprises a T- helper epitope.
- the T- helper epitope is selected from the group consisting of a flu, hepatitis B, tetanus toxin, diphtheria toxin, and measles T-helper epitope.
- the T-helper epitope comprises an amino acid sequence selected from the group consisting of SEQ ID Nos. 49-77.
- the CD4+ T-helper cell epitope comprises an amino acid sequence selected from the group consisting of SEQ ID Nos. 49-77.
- the coronavirus is a human coronavirus. In certain embodiments, the coronavirus is an alpha coronavirus. In certain embodiments, the coronavirus is a beta coronavirus. In certain embodiments, the coronavirus is selected from the group consisting of 229E, NL63, OC43, HKU1, MERS-CoV, SARS-CoV, and SARS- CoV-2. In certain embodiments, the coronavirus is SARS-CoV-2. In certain embodiments, the antigen comprises at least one of a B-cell epitope, CD4+ T-cell epitope, or CD8+ T-cell epitope.
- the antigen is a modified SARS-CoV-2 Spike protein epitope.
- the modified SARS-CoV-2 Spike protein epitope comprises at least one modification selected from the group consisting of a linker, a carboxamide, hairpin cap, a cysteine residue, and a furin cleavage site, a serin protease cleavage site, and an amino acid substitution.
- the antigen comprises an amino acid sequence selected from the group consisting of SEQ ID Nos. 96-193. In certain embodiments, the antigen comprises an amino acid sequence consisting of an amino acid sequence selected from the group consisting of SEQ ID Nos. 96-193. In certain embodiments, the antigen consists of an amino acid sequence selected from the group consisting of SEQ ID Nos. 96-193.
- the lipoprotein further comprises one or more linkers.
- the antigen is coupled to the lipopeptide building block via the one or more linkers.
- the amphipathic domain is coupled to the lipid moiety via the one or more linkers.
- the one or more linkers is a peptide linker.
- the one or more linkers comprises an amino acid sequence selected from the group consisting of SEQ ID Nos. 194-232.
- the lipoprotein further comprises a purification tag coupled to the antigen.
- the purification tag is removable by treatment with a protease.
- the purification tag comprises an amino acid sequence selected from the group consisting of SEQ ID Nos. 233-242.
- a lipoprotein comprising: (a) lipopeptide building block comprising: (i) a lipid moiety, (ii) an amphipathic domain, and (iii) a T-helper cell epitope; and (b) an antigen of SARS-CoV-2 coupled to the lipopeptide building block.
- an immunogenic composition comprising the lipoprotein of any one of the preceding embodiments. In certain embodiments, the immunogenic composition further comprises an adjuvant.
- the adjuvant is selected from the group consisting of aluminum, amorphous aluminum hydroxyphosphate sulfate (AAHS), aluminum hydroxide, aluminum phosphate, potassium aluminum sulfate (Alum), monophosphoryl lipid A (MPL), squalene, cytosine phosphoguanine, QS-21, microcrystalline tyrosine, MF59, mannide monooleate, GLA, SLA, E6020, resiquimod (R848), imidazoquinolines, imiquimod, 3M-052, 2',3'-cGAMP, 3', 3'- cGAMP, cGMP, cAMP, AMP, muramyl dipeptide, poly I:C, CpGand combinations thereof.
- AAHS amorphous aluminum hydroxyphosphate sulfate
- Al hydroxide aluminum phosphate
- Al phosphate aluminum phosphate
- MPL monophosphoryl lipid A
- squalene cytosine phospho
- a lipoprotein or an immunogenic composition of any one of the preceding embodiments wherein the lipoprotein provides protective immunity to a subject against the coronavirus.
- the lipoprotein or immunogenic composition provides protective immunity to a subject against the coronavirus for at least about 1 month, about 2 months, about 3 months, about 4 months, about 5 months, about 6 months, about 9 months, about 12 months, about 18 months, about 2 years, about 3 years, about 4 years, about 5 years, or about 10 years after administration to the subject.
- the lipoprotein induces an immune response in a subject sufficient to provide protective immunity to the subject against the coronavirus.
- the lipoprotein or the immunogenic composition induces the production of antibodies against at least a portion of the coronavirus spike protein.
- a single dose of the lipoprotein induces an immune response in a subject sufficient to provide protective immunity to the subject against the coronavirus.
- two doses of the lipoprotein induce an immune response in a subject sufficient to provide protective immunity to the subject against the coronavirus.
- the lipoprotein does not induce antibody-dependent enhancement.
- the lipoprotein has an efficacy rate of greater than about 20%, greater than about 30%, greater than about 40%, greater than about 50%, greater than about 60%, greater than about 70%, greater than about 80%, or greater than about 90%.
- the lipoprotein has an reactogenicity rate of less than about 20%, less than about 15%, less than about 10%, less than about 8%, less than about 5%, less than about 3%, less than about 2%, or less than about 1%.
- a method of immunizing a subject against a coronavirus comprising administering to the subject the lipoprotein or the immunogenic composition of any one of the preceding embodiments.
- disclosed herein is a method of preventing or reducing risk of coronavirus infection in a subject comprising administering to the subject the lipoprotein or the immunogenic composition of any one of the preceding embodiments.
- a method of treating a coronavirus infection in a subject comprising administering to a subject the lipoprotein or the immunogenic composition of any one of the preceding embodiments.
- a method of reducing symptoms of a coronavirus infection in a subject comprising administering to the subject the lipoprotein or the immunogenic composition of any one of the preceding embodiments.
- the subject is human.
- the subject is immunocompromised.
- the subject is 60 years of age or older.
- the subject is a pediatric subject.
- a method of immunizing a subject against a coronavirus comprising: (a) administering to the subject a first immunogenic composition; and (b) administering to the subject a second immunogenic composition, the second immunogenic composition comprising a lipoprotein, the lipoprotein comprising (1) a lipopeptide building block and (2) a first antigen of a coronavirus, wherein the lipopeptide building block comprises lipid moiety and an amphipathic domain, and wherein the second immunogenic composition is heterologous to the first immunogenic composition; and wherein the second immunogenic composition is administered to the subject before or after the first immunogenic composition.
- the second immunogenic composition is administered to the subject before the lipoprotein.
- the second immunogenic composition is administered to the subject after the lipoprotein.
- FIG. 1 shows the structure of Construct No. 567 (in Table 6), specifically C- terminal structure of the peptide is depicted. SEQ ID NO:719.
- FIG. 2 shows the structure of a lipoprotein construct having a Pam2Cys structure at the C-terminus.
- FIG. 3 shows the structure of a lipoprotein construct having a Pam3Cys structure at the C-terminus.
- FIG. 4 shows the structure of a lipoprotein construct having a Pam3Cys structure at the C-terminus.
- FIG. 5 shows the structure of a lipoprotein construct having a Pam3Cys structure at the C-terminus.
- the present disclosure relates to a lipoprotein comprising (1) a lipopeptide building block (BB) (see, Section I herein) comprising a lipid moiety (LM) (see, Section I. A herein) and an amphipathic domain (AD) (see, Section I.B herein) and (2) an antigen of a coronavirus (A) (see Section II herein).
- BB lipopeptide building block
- AD amphipathic domain
- A an antigen of a coronavirus
- the lipoprotein has the structure: BB-A, where BB represents the lipopeptide building block and A represents the antigen.
- the lipoprotein has the structure: LM-AD-A, where LM represents the lipid moiety, AD represents the amphipathic domain, and A represents the antigen.
- the lipopeptide building block and the antigen of a coronavirus are covalently linked, either directly or indirectly through a linker (L) (see, Section III herein).
- the lipoprotein has the structure: LM-L-AD-L-A.
- the lipopeptide building block further comprises a T-helper epitope (TH) (see, Section I.C herein), which can be linked, either directly or indirectly through a linker (L), to the amphipathic domain and the antigen.
- TH T-helper epitope
- the lipoprotein has the structure LM-AD-TH-A, wherein LM represents the lipid moiety, AD represents the amphipathic domain, TH represents the T-helper epitope, and A represents the antigen.
- each component of the lipoprotein can be either covalently linked to each other, either directly or indirectly through a linker (L).
- the lipoprotein has the structure LM-L-AD-L-TH-L-A, where each instance of linker (L) is optional.
- the lipoprotein construct can comprise the sequences set forth in Table 6 herein (see, Section IV herein).
- the lipoprotein is an immunogenic composition (see, Section V herein). In certain embodiments, disclosed herein are immunogenic compositions comprising the lipoprotein disclosed herein. In certain embodiments, the lipoprotein can be used to treat, prevent, or reduce the symptoms of a coronavirus infection (see, Section VI herein). In certain embodiments, the lipoprotein can be used as a coronavirus vaccine. In certain embodiments, the lipoprotein is a synthetic virus-like particle (SVLP).
- SVLP synthetic virus-like particle
- the disclosed lipoproteins which are SVLPs and thus exhibit a native virus-like shape can result in increased cross-reactivity and increased titers of functional antibodies, providing an advantage in utilizing the disclosed lipoproteins as vaccines.
- the lipoprotein is a nanomicelle.
- the lipoprotein comprises a lipopeptide building block.
- the lipopeptide building block comprises a lipid moiety as disclosed in Section I. A herein and an amphipathic domain as disclosed in Section I.B herein.
- the lipopeptide building block further comprises a T-helper epitope as disclosed in Section I.C herein.
- the lipid moiety is a Toll-like receptor (TLR) agonist, for example, a TLR-1, TLR-2, TLR-4, TLR-5, TLR-6, or TLR- 10 agonist. In certain embodiments, the lipid moiety is a TLR-2 agonist.
- TLR Toll-like receptor
- the lipid moiety comprises hydrocarbyl chains. In certain embodiments, the lipid moiety comprises one or more hydrocarbyl chains. In certain embodiments, the lipid moiety comprises two hydrocarbyl chains. In certain embodiments, the lipid moiety comprises three hydrocarbyl chains. In certain embodiments, the lipid moiety is a phospholipid.
- the phospholipid can comprise either ester- or ether-linked extended alkyl or alkenyl side.
- the phospholipid comprises enantiomers of 1,2- dipalmitoyl-sn-glycero-3-phosphoethanolamine. In certain embodiments, the phospholipid comprises achiral analogues, including, but not limited to, l,3-dipalmitoyl-glycero-2- phosphoethanolamine.
- the lipid moiety is selected from one of Formula LM1 to LM8:
- n 1, 2, 3 or 4, or
- R1 and R ⁇ in formulas LM 7 and LM 8 are independently of each other hydrocarbyl.
- the lipid moiety is di-palmitoyl-S-glycerylcysteinyl of formula LM3, wherein R1 and R ⁇ are palmitoyl, and R ⁇ is H or acetyl.
- the hydrocarbyl or hydrocarbyl chain is a straight or branched alkyl or alkenyl chain consisting of at least 7 carbon atoms, between 8 and 50 carbon atoms, between 8 and 25 carbon atoms, and optionally one, two or three double bonds.
- Alkenyl has one, two or three double bonds in the chain, each with E or Z geometry, as is customarily found in natural fatty acids and fatty alcohols.
- hydrocarbyl or “hydrocarbyl chain” is branched alkyl or alkenyl, for example alkyl bearing a methyl or ethyl substituent at the second or third carbon atom counted from the end of the chain, as e.g. as in 2-ethyl-hexyl.
- lower alkyl means alkyl with 1 to 7 carbon atoms, including, for example, 1 to 4 carbon atoms, such as methyl, ethyl, n-propyl, iso-propyl, n-butyl, sec-butyl, iso-butyl or tert-butyl.
- the lipid moiety is:
- the lipid moiety is:
- the lipid moiety is: wherein R 3 is -C(O)Cn-i5alky or -C(O)CisH3i.
- the lipid moiety is: wherein R 3 is -C(O)Cn-i5alky or -C(O)Ci5H3i.
- the lipid moiety is:
- the lipid moiety is:
- the lipid moiety is:
- the lipid moiety is moiety is selected from the group consisting of Cys((R)-2,3-di(palmitoyloxy)-2-propyl) (also referred to as: Pam2Cys or dipalmitoyl-S-glyceryl cysteine), Cys((S)-2,3-di(palmitoyloxy)-2-propyl), Cys((R)-2,3- di(palmitoyloxy)-2-propyl-N-palmitoyl) (also referred to as: Pam3Cys or tripalmitoyl-S- glyceryl cysteine), unsaturated Pam3Cys, unsaturated Pam2Cys, N, N’ -dipalmitoyl.
- Cys((R)-2,3-di(palmitoyloxy)-2-propyl) also referred to as: Pam2Cys or dipalmitoyl-S-glyceryl cysteine
- the lipid moiety comprises Pam2Cys. In certain embodiments, the lipid moiety consists of Pam2Cys. In certain embodiments, the lipid moiety comprises Pam3Cys. In certain embodiments, the lipid moiety consists of Pam3Cys.
- the amphipathic domain has an amphipathic alpha helical structure with opposing polar and nonpolar faces oriented along the long axis of the helix.
- the amphipathic domain has amphipathic beta strand structure in which hydrophobic side-chains point in one direction and polar side-chains in the other.
- the amphipathic domain associates into a helical bundle.
- the amphipathic domain directs formation a coiled-coil. In certain embodiments, the amphipathic domain directs formation of an amphipathic beta sheet with at least two parallel beta strands in which hydrophobic side-chains point in one direction and polar side-chains in the other.
- the amphipathic domain is a peptide structure comprising one chain. In certain embodiments, the amphipathic domain is a peptide structure comprising at least two chains. In certain embodiments, the amphipathic domain comprises parallel beta strands. In certain embodiments, the amphipathic domain comprises at least two peptide chains are associated into a bundle. In certain embodiments, the at least two peptide chains each have an alpha helical secondary structure and are associated into a bundle. Accordingly, in certain embodiments, the amphipathic domain comprises, or consists of, a coiled-coil domain. In certain embodiments, the coiled-coil domain directs formation of helical bundles.
- amphipathic domains including coiled-coil domains, that are suitable in certain embodiments disclosed herein are disclosed in WO 2008/068017, W02015/082501, WO 2018/229156, WO 2020/127728, WO 2009/109428, WO 2011/112999, US 9,044,514, US 9,994,646, US 7,811,577, US 8,728,785, each of which are herein incorporated by reference.
- the amphipathic domain comprises multiple repeat units consecutively linked to each other.
- the repeat units of the amphipathic domain segment may be identical or may be different, e.g. may contain at least one discontinuity, such as an insertion, deletion or exchange of at least one amino acid within the repeat unit.
- 1, 2, 3 or 4 amino acids within the repeat unit may be inserted, deleted, or exchanged.
- the amphipathic domain comprises or consists of 2 to 10 repeat units including 2, 3, 4, 5, 6, 7, 8, 9 and 10 repeat units, 3 to 8 repeat units including 3, 4, 5, 6, 7, 8 repeat units, or 4 repeat units.
- the amphipathic domain comprises at least two heptad repeats (e.g. two, three, four, five, six, seven, eight, nine, ten, or more, repeat units).
- the amphipathic domain can be based on canonical repeat units and non- canonical repeat units.
- the amphipathic domain comprises canonical tandem heptad repeats that may form right-handed amphipathic alpha-helices, which then assemble to form helical bundles with left-handed coiled coils.
- the coiled-coil domain comprises non-canonical, non-heptad-based repeats that form coiled coils that are not necessarily left-handed or even regular supercoils.
- Repeat units of amphipathic domains have a sequence with a certain number of amino acids, wherein the positions of the amino acids are labelled as lowercase letters.
- the repeat unit of the coiled-coil domains consists of 7 to 15 amino acids or 7 to 11 amino acids.
- the coiled-coil domain comprises or consists of 7 amino acids, wherein the seven amino acid positions are designated with letters a, b, c, d, e, f and g.
- the heptad motif includes amino acids having hydrophobic residues at positions a and d, and polar, helix- favoring residues at the other residues.
- each of a and d can independently be selected from Ala, He, Leu, Met, Vai, Phe, Trp and Tyr.
- residues a and d can each independently be Gin or Asn.
- residues a and d each do not comprise N or Q.
- residues b, c, e, f and g are selected from Ala, Glu, Lys and Gin.
- the amphipathic domain comprises or consists of 2 to 10 repeat units or 3 to 8 repeat units. In certain embodiments, the amphipathic domain comprises or consists of 4 repeat units. In certain embodiments, the amphipathic domain comprises or consists of 15, 11 or 7 amino acids. In certain embodiments, the amphipathic domain consists of 7 amino acids (heptad motif).
- the amphipathic domain comprises 3-8 tandemly linked heptad motifs, wherein positions a and d in each heptad motif (abcdefg) contain alpha-amino acids belonging to the Group 1 and/or to the Group 2 as defined herein below.
- positions a and d in each heptad motif (abcdefg) contain alpha-amino acids belonging to the Group 1 and/or to the Group 2 as defined herein below.
- not more than two of all the a and d positions may be occupied by any amino acid residue belonging to the Group 3, and not more than one of all the a and d positions may be occupied by any amino acid residue belonging to the Group 4 or Group 5 or by glycine.
- positions b, c, e, f and g are each independently selected from alphaamino acids belonging to the Groups 3, 4 and 5.
- At least one amino acid in positions b, c, e, f and g are hydrophobic. In certain embodiments, at least two amino acids in positions b, c, e, f and g are hydrophobic. In certain embodiments, at least three amino acids in positions b, c, e, f and g are hydrophobic. In certain embodiments, positions b, c, e, f and g, are each independently selected from a hydrophobic amino acid. In certain embodiments, positions b, c, e, f and g are each independently selected from amino acids belonging to the Groups 1 and 2.
- Group 1 comprises alpha-amino acid residues with small to medium sized hydrophobic side chains.
- a hydrophobic residue refers to an amino acid side chain that is uncharged at physiological pH and that is repelled by aqueous solution.
- These side chains generally do not contain hydrogen bond donor groups, such as primary and secondary amides, primary and secondary amines and the corresponding protonated salts thereof, thiols, alcohols, ureas or thioureas. However, they may contain hydrogen bond acceptor groups such as ethers, thioethers, esters, tertiary amides, or tertiary amines. Genetically encoded amino acids in this group include alanine, isoleucine, leucine, methionine and valine.
- Group 2 comprises amino acid residues with aromatic or heteroaromatic side chains.
- An aromatic amino acid residue refers to a hydrophobic amino acid having a side chain containing at least one ring having a conjugated aromatic pi-electron system.
- it may contain additional hydrophobic groups such as lower alkyl, aryl or halogen, hydrogen bond donor groups such as primary and secondary amines, and the corresponding protonated salts thereof, primary and secondary amides, alcohols, and hydrogen bond acceptor groups such as ethers, thioethers, esters, tertiary amides or tertiary amines.
- Genetically encoded aromatic amino acids include phenylalanine and tyrosine.
- a heteroaromatic amino acid residue refers to a hydrophobic amino acid having a side chain containing at least one ring having a conjugated aromatic pi-system incorporating at least one heteroatom such as O, S and N .
- residues may contain hydrogen bond donor groups such as primary and secondary amides, primary and secondary amines and the corresponding protonated salts thereof, alcohols, and hydrogen bond acceptor groups such as ethers, thioethers, esters, tertiary amides or tertiary amines.
- Genetically encoded heteroaromatic amino acids include tryptophan and histidine.
- Group 3 comprises amino acids containing side chains with polar non-charged residues.
- a polar non-charged residue refers to a hydrophilic side chain that is uncharged at physiological pH, but that is not repelled by aqueous solutions.
- Such side chains typically contain hydrogen bond donor groups such as primary and secondary amides, primary and secondary amines, thiols, and alcohols. These groups can form hydrogen bond networks with water molecules. In addition, they may also contain hydrogen bond acceptor groups such as ethers, thioethers, esters, tertiary amides, or tertiary amines.
- Genetically encoded polar noncharged amino acids include asparagine, cysteine, glutamine, serine and threonine.
- Non- proteinogenic polar amino acids include citrulline and homocysteine.
- Group 4 comprises amino acids containing side chains with polar cationic residues and acylated derivatives thereof, such as acylamino-derived residues and urea-derived residues.
- Polar cationic side chains refer to a basic side chain, which is protonated at physiological pH.
- Genetically encoded polar cationic amino acids include arginine, lysine and histidine. Omitine is an example for a urea-derived amino acid residue.
- Group 5 comprises amino acids containing side chains with polar anionic residues.
- Polar anionic refers to an acidic side chain, which is deprotonated at physiological pH.
- Genetically encoded polar anionic amino acids include aspartic acid and glutamic acid, for example, a polar anionic residue is -(CTLjaCOOH, wherein "a" is 1 to 4.
- the amphipathic domain includes between 3 to 8 tandemly linked heptad motifs, wherein each heptad motif (abcdefg) may have any one of the following sequences: Ixxlxxx (referring respectively to the positions abcdefg); lxx2xxx (referring respectively to the positions abcdefg); 2xxlxxx (referring respectively to the positions abcdefg); or 2xx2xxx (referring respectively to the positions abcdefg); wherein 1 is a genetically encoded amino acid from Group 1; 2 is a genetically encoded amino acid from Group 2; and wherein x is a genetically encoded amino acid from Groups 1, 2, 3, 4 or 5 or glycine.
- each heptad motif may have any one of the following sequences: Ixxlxxx (referring respectively to the positions abcdefg); lxx2xxx (referring respectively to the positions abcdefg); 2xxlxxx (referring respectively to the positions abcdefg); or 2xx2xx
- the alpha-amino acid with a hydrophobic side chain is selected from alanine, isoleucine, leucine, methionine and valine; the alpha-amino acid with aromatic or heteroaromatic residue is selected from phenylalanine, tyrosine, tryptophan and histidine; the alpha-amino acid with polar non- charged residue is selected from asparagine, cysteine, glutamine, serine and threonine; the alpha-amino acids with polar cationic residue is selected from arginine, lysine and histidine; and the alpha-amino acid with polar anionic residue is selected from aspartic acid and glutamic acid.
- the amphipathic domain comprises or consists of amino acid sequences identified in naturally occurring peptides and proteins, but excluding those of human origin, for example, coiled-coil domains identified in viral and bacterial proteins.
- the amphipathic domain can be (XiX2X3X4XsX6X7)n (SEQ ID NO: 722), wherein Xi is a hydrophobic amino acid residue or asparagine, X2, X3, and Xe are each any amino acid residue, X4 is a hydrophobic amino acid residue, X5 and X7 are each a charged amino acid residue, and n is from 1 to 10.
- the amphipathic domain can be (lEKKIEXi)n (SEQ ID NO:723), wherein Xi is selected from A, G, T, and S, and n is 2.
- the coiled-coil domain includes E/K salt bridges between the b and f positions IEEKIKA/G/T/S (SEQ ID NO:724)and IECKIAA (SEQ ID NO:725).
- the amphipathic domain includes a cysteine residue for conjugation.
- exemplary amino acid sequences that can be included in the amphipathic domain are listed in Table 1 below, wherein Xi is selected from Vai, He, Leu, and Phe, X2 is selected from Glu, Lys, Arg, His, Ser, Thr, Asn, Gin, and Cys, X3 is selected from Glu, Lys, Arg, His, Ser, Thr, Asn, Gin, X4 is selected from He, Leu, Phe, X5 is selected from Glu, Lys and Gly, and Xe is selected from Ala, Gly, Lys, and any other hydrophilic amino acid, and variants thereof in which one, two, or three amino acids are replaced by other amino acids or are deleted. [0073] Table 1. Amphipathic Domain Sequences.
- the amphipathic domain comprises an amino acid sequence selected from the group consisting of SEQ ID Nos: 1-48
- the amphipathic domain comprises an amino acid sequence consisting of an amino acid sequence selected from the group consisting of: SEQ ID NOs: 1-48.
- the amphipathic domain consists of an amino acid sequence selected from the group consisting of SEQ ID NOs: 1-48.
- the lipopeptide building block further comprises a T- helper epitope.
- the T-helper epitope is selected from a flu, hepatitis B, tetanus toxin, diphtheria toxin, and measles T-helper epitope.
- the T-helper epitope is a flu T-helper epitope.
- the T-helper epitope is a tetanus toxin T-helper epitope.
- the T-helper epitopes that can be included in the lipopeptide building block are provided in Table 2 below, and variants thereof in which one, two, or three amino acids are replaced by other amino acids or are deleted.
- the T-helper epitope comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 49-77.
- the T-helper epitope comprises an amino acid sequence consisting of an amino acid sequence selected from the group consisting of: SEQ ID NOs: 49-77.
- the T-helper epitope consists of an amino acid sequence selected from the group consisting of SEQ ID NOs: 49-77. D. Signal Sequence
- the lipopeptide building block comprises a signal sequence for cell-culture based expression of the lipopeptide building block.
- the signal sequence is fused to the N-terminus of the lipopeptide building block and then cleaved upon processing of the lipopeptide. Exemplary signal sequences that can be included in the lipopeptide building block are provided in Table 3 below:
- the signal peptide is cleaved from the lipopeptide for use with the methods of treatment disclosed herein.
- the signal peptide comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 78-95.
- the signal peptide comprises an amino acid sequence consisting of an amino acid sequence selected from the group consisting of: SEQ ID NOs: 78-95.
- the signal peptide consists of an amino acid sequence selected from the group consisting of SEQ ID NOs: 78-95.
- the lipoprotein can comprise a coronavirus antigen.
- the coronavirus antigen is conjugated directly or indirectly through a linker to a component of the lipopeptide building block.
- the coronavirus antigen is connected, either directly or indirectly through a linker, through its N- or C-terminus, to the N- or to the C-terminal of the amphipathic domain, or to an amino acid side chain of the amphipathic domain.
- the coronavirus antigen is connected, either directly or indirectly through a linker, through its N- or C-terminus, to the N- or to the C-terminal of the T-helper epitope, or to an amino acid side chain of the T-helper epitope.
- the coronavirus antigen is connected to a component of the lipopeptide building block through a side chain residue of the coronavirus antigen, for example, through a terminal or internal aspartic acid, glutamic acid, lysine, ornithine or cysteine side chain.
- the coronavirus antigen is a human coronavirus antigen.
- the coronavirus antigen is an alpha coronavirus antigen.
- the coronavirus antigen is a beta coronavirus antigen.
- the coronavirus antigen is selected from the group consisting of a 229E, NL63, OC43, HKU1, MERS-CoV, SARS-CoV, and SARS-CoV-2 antigen.
- the coronavirus antigen is a SARS-CoV-2 antigen.
- the antigen is selected from a B-cell epitope, CD4+ T-cell epitope, and CD8+ T-cell epitope.
- the antigen can comprise one or more of a B-cell epitope, CD4+ T-cell epitope, and CD8+ T-cell epitope.
- the antigen comprises a B-cell epitope.
- the antigen comprises a CD4+ T-cell epitope.
- the antigen comprises a CD8+ T-cell epitope.
- the antigen comprises a modified Spike protein epitope.
- the antigen comprises one or more epitopes from different coronaviruses.
- the antigen is a modified SARS-CoV-2 Spike protein epitope.
- the modified SARS-CoV-2 Spike protein epitope comprises at least one modification selected from the group consisting of a hairpin cap, a helix cap, a cysteine residue, a furin protease cleavage site, a serin protease cleavage site, a linker, a carboxamide, and an amino acid substitution.
- the amino acid substitution improves solubility. Accordingly, the amino acid substitution can be a hydrophilic amino acid.
- a hydrophobic amino acid may be substituted by a charged amino acid, such as Asp, Glu, Arg, Lys, ornitin (Orn), 1,3-diaminopropionic acid (Dap), or 1,4-diaminobutyric acid (Dab), 4-amino-proline (Amp).
- a hydrophobic amino acid may be substituted by a less hydrophobic amino acid such as Ala. In certain embodiments, the amino substitution improves the stability.
- a small hydrophobic amino acid can be substituted by a larger hydrophobic amino acid to fill an empty cavity inside the lipoprotein or an L-amino acid may be substituted by a D-amino acid to increase the stability towards proteases.
- Certain coronavirus antigen sequences that can be included in the disclosed lipoprotein are provided in Table 4 below, and variants thereof in which one, two, or three amino acids are replaced by other amino acids or are deleted.
- SEQ ID NOs: 63-70 are wild-type receptor binding domain peptides of the Spike protein SI subunit from SARS-CoV-2, SARS-CoV-1, HuCoV-229E, HuCoV-OC43, HuCoV-NL63, HuCoV-HKUl/BRA/22/2007, HuCoV-HKUl or MERS, respectively;
- SEQ ID NOs: 71-73 are wild-type receptor binding motif peptides from SARS-CoV-2, SARS-CoV-1 or MERS;
- SEQ ID NOs: 74-81 are wild-type Spike protein SI subunit SD1 peptides from SARS-CoV- 2, SARS-CoV-1, HuCoV-229E, HuCoV-OC43, HuCoV-NL63, HuCoV-
- SEQ ID NOs: 82-89 are wt Spike SD2 peptides from SARS-CoV-2, SARS-CoV-1, HuCoV-229E, HuCoV-OC43, HuCoV-NL63, HuCoV-HKUl/BRA/22/2007, HuCoV-HKUl or MERS;
- SEQ ID NOs: 90-96 are wild-type Spike protein S2 subunit FP peptides from SARS-CoV-2, SARS-CoV-1, HuCoV-229E, HuCoV-OC43, HuCoV-NL63, HuCoV-HKUl/BRA/22/2007 or MERS;
- SEQ ID NOs: 97- 103 are wild-type Spike protein S2 subunit HR1 peptide peptides from SARS-CoV-2, SARS- CoV-1, HuCoV-229E, HuCoV-OC43, HuCoV-NL63, HuCoV-HKUl
- the coronavirus antigen comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 96-193.
- the coronavirus antigen comprises an amino acid sequence consisting of an amino acid sequence selected from the group consisting of: SEQ ID NOs: 96-193.
- the coronavirus antigen consists of an amino acid sequence selected from the group consisting of SEQ ID NOs: 96-193.
- the lipoprotein comprises a first coronavirus antigen and a second coronavirus antigen, wherein the first and second coronavirus antigens are connected via a linker, e.g., a peptide linker as disclosed herein.
- a linker e.g., a peptide linker as disclosed herein.
- the N-terminus of the first coronavirus antigen is connected to the C-terminus of the second coronavirus antigen.
- the C-terminus of the first coronavirus antigen is connected to the N-terminus of the second coronavirus antigen.
- the components of the lipoprotein can be linked via various linkers.
- the linkers can include linkers having the structure LI to L16 below and/or short peptides of 2 to 20 amino acids (as discussed below).
- the amphipathic domain (AD) can be covalently linked to the lipid moiety (LM) at or near one terminus, i.e., the N-terminus or the C-terminus.
- the amphipathic domain is linked to the lipid moiety via the N-terminus of the amphipathic domain.
- the lipid moiety is directly linked to the amphipathic domain to form the structure: LM-AD.
- the lipid moiety is indirectly linked to the amphipathic domain via a linker to form the structure: LM-L-AD.
- the coronavirus antigen can be linked to the lipopeptide building block (BB), for example, to the coiled-coil domain or to the T-helper epitope, via a linker, to form the structure BB-L-A.
- the components of the lipoprotein for example, the amphipathic domain and the lipid moiety, or the coronavirus antigen and the BB, are directly linked, this can be accomplished, for example, through an amide bond between a lipid moiety carbonyl function and an amino function, e.g. the N-terminal amino function, of amphipathic domain.
- certain lipid moieties e.g., LM1, LM2, and LM8 (as defined below), are connected through an amide bond between their amine function and a carboxy function, e.g., the C-terminal carboxy function, of the amphipathic domain.
- linkers and coupling strategies include, but not limited to, linkers based on dicarboxylic acid derivatives, linkers containing one or multiple ethylene glycol units, amino acid residues (including a-, P-, y-, 6-amino acids), or sugar (carbohydrate) units, or containing heterocyclic rings.
- linkers LI to L16 may be connected to the lipid moiety and amphipathic domain as follows.
- a carbonyl function shown for LI to L16 may be connected to an amino function of a suitable lipid moiety and/or an amino function, e.g. the N-terminal amino function, of the amphipathic domain through an amide bond.
- a carbonyl function shown for LI to LI 6 may be connected to a lipid moiety by replacement of the corresponding carbonyl function in particular lipid moieties LM3 to LM7.
- the terminal -CH2 group of L8 may be connected to an amino function of a suitable lipid moiety, an amino function, e.g. the N-terminal amino function, of the amphipathic domain, or a carbonyl function of a suitable lipid moiety.
- an amino function e.g. the N-terminal amino function
- the linker can be connected via a terminus of the amphipathic domain, or through a side chain residue of the amphipathic domain, for example, through such as a terminal or internal aspartic acid, glutamic acid, lysine, ornithine or cysteine side chain.
- the coronavirus antigen can be conjugated directly or through a linker, either at the N- or C-terminus of the coronavirus antigen, and is connected either to the N- or to the C- terminal of the lipopeptide building block, or optionally to an amino acid side chain.
- the coronavirus antigen can be conjugated to the lipopeptide building block through a side chain residue of the coronavirus antigen, such as a terminal or internal aspartic acid, glutamic acid, lysine, ornithine or cysteine side chain.
- Suitable linkers for linking the coronavirus antigen to the lipopeptide building block include short peptides of 2 to 20 amino acids, hydroxyalkyl- or aminoalkyl-carboxylic acids, substituted or unsubstituted polyalkylenoxy glycols, e.g., containing one to twelve C2 and/or C3 alkylenoxy units, polyalkylenoxy glycol block co-polymers (e.g.
- oligosaccharides which may comprise acetyl, glycerol-phosphate or other substituents at one or more positions, polysaccharides such as poly(sialylic acid) and derivatives (e.g.
- peptide conjugates thereof, proteinogenic or non-proteinogenic amino acids, and Cl -C8 saturated or unsaturated hydrocarbons, and may comprise one or more of the following functional groups: a disulphide bond, amine, amide, acetal, ester, ether, thioether, hydrazone, hydrazide, imine, oxime, urea, thiourea, carbonate, iminocarbonate, amidine, amide, imide, an alkyl sue- cinimide, which may also be hydrolyzed to an amide, sulphonamide, sulfone, or a heterocyclic ring comprising one or more atoms selected from nitrogen and oxygen, for example a triazole, and combinations thereof.
- a disulphide bond amine, amide, acetal, ester, ether, thioether, hydrazone, hydrazide, imine, oxime, urea, thiourea, carbonate, iminocarbonate
- Exemplary Peptide Linkers [00104]
- the peptide linker comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 194-232.
- the peptide linker comprises an amino acid sequence consisting of an amino acid sequence selected from the group consisting of: SEQ ID NOs 194-232.
- the peptide linker consists of an amino acid sequence selected from the group consisting of SEQ ID NOs: 194-232.
- the lipoprotein comprises a structure selected from the group consisting of Constructs 1-573 as set forth in Table 6. In certain embodiments, the lipoprotein consists of a structure selected from the group consisting of Constructs 1-573 as set forth in Table 6. In certain embodiments, the lipoprotein comprises a structure as shown in Figures 1, 2, 3, 4, or 5. In certain embodiments, the lipoprotein comprises a structure as shown in Figure 1. In certain embodiments, the lipoprotein comprises a structure as shown in Figure 2. In certain embodiments, the lipoprotein comprises a structure as shown in Figure 3. In certain embodiments, the lipoprotein comprises a structure as shown in Figure 4. In certain embodiments, the lipoprotein comprises a structure as shown in Figure 5.
- the lipoprotein constructs can comprise a purification tag coupled to the coronavirus antigen, for example, a hexa-His tag.
- the purification tag is directly coupled to the lipoprotein construct.
- the purification tag is indirectly coupled to the lipoprotein construct via a linker.
- the purification tag is removable by treatment with a protease.
- the purification tag comprises one of the amino acid sequences set forth in Table 7.
- the purification tag comprises an amino acid sequence selected from the group consisting of SEQ ID Nos: 233-242.
- the purification tag comprises an amino acid sequence consisting of an amino acid sequence selected from the group consisting of SEQ ID NOs: 231-240.
- the purification tag consists of an amino acid sequence selected from the group consisting of SEQ ID NOs: 233-242.
- the lipoprotein is an immunogenic composition.
- the lipoprotein is a vaccine, for example, a coronavirus vaccine.
- the immunogenic composition is a vaccine.
- the immunogenic composition comprises the lipoprotein disclosed herein, either alone or in combination with a pharmaceutically acceptable carrier.
- the immunogenic composition comprises one or more adjuvants selected from, for example, a mineral salt (e.g. aluminium hydroxide, aluminium phosphate, aluminium sulfate, calcium phosphate), monophosphoryl lipid A (MPL), plant extracts containing saponins (e.g. QS-21), imidazo-quinolines (e.g.
- Imiquimod muramyl dipeptides and tripeptides, lipopeptides, oilin- water emulsions (e.g. Montanide ISA 720), cytokines (e.g. IL-2 or GM-CSF), mycobacterial and bacterial derivatives (e.g. Freund's complete adjuvant), BCG, nucleic acid derivatives (e.g. polylC) and other adjuvants known to those skilled in the art.
- cytokines e.g. IL-2 or GM-CSF
- mycobacterial and bacterial derivatives e.g. Freund's complete adjuvant
- BCG nucleic acid derivatives
- nucleic acid derivatives e.g. polylC
- other adjuvants known to those skilled in the art.
- the adjuvant is selected from the group consisting of aluminum, amorphous aluminum hydroxyphosphate sulfate (AAHS), aluminum hydroxide, aluminum phosphate, potassium aluminum sulfate (Alum), monophosphoryl lipid A (MPL), squalene, cytosine phosphoguanine, QS-21, microcrystalline tyrosine, MF59, mannide monooleate, GLA, SLA, E6020, resiquimod (R848), imidazoquinolines, imiquimod, 3M-052, 2',3'-cGAMP, 3', 3'- cGAMP, cGMP, cAMP, AMP, muramyl dipeptide, poly I:C, CpG and combinations thereof.
- AAHS amorphous aluminum hydroxyphosphate sulfate
- Al hydroxide aluminum phosphate
- Al phosphate aluminum phosphate
- MPL monophosphoryl lipid A
- squalene cytosine phospho
- the immunogenic composition is encapsulated in or attached to bio-degradable polymers, which may for example be useful for controlled release, for example polylactic acid, poly-epsilon-caprolactone, polyhydroxybutyric acid, poly orthoesters, poly acetals, poly dihydropyrans, poly cyanoacrylates, and crosslinked or amphipathic block copolymers of hydrogels, or may be formulated in liposomes.
- bio-degradable polymers which may for example be useful for controlled release, for example polylactic acid, poly-epsilon-caprolactone, polyhydroxybutyric acid, poly orthoesters, poly acetals, poly dihydropyrans, poly cyanoacrylates, and crosslinked or amphipathic block copolymers of hydrogels, or may be formulated in liposomes.
- the immunogenic composition can be prepared according to conventional means known to a person of ordinary skill in the art, such as, for example, dissolving and lyophilizing processes and/or may comprise excipients, for example preservatives, stabilizers, wetting agents, tonicity adjusting agents and/or emulsifiers, solubilizers, salts for regulating osmotic pressure and/or buffering substances to stabilize the pH.
- excipients for example preservatives, stabilizers, wetting agents, tonicity adjusting agents and/or emulsifiers, solubilizers, salts for regulating osmotic pressure and/or buffering substances to stabilize the pH.
- excipients for example preservatives, stabilizers, wetting agents, tonicity adjusting agents and/or emulsifiers, solubilizers, salts for regulating osmotic pressure and/or buffering substances to stabilize the pH.
- salts for regulating osmotic pressure and/or buffer
- the immunogenic composition comprises from about 0.05% to about 99%, from about 0.05% to about 75%, from about 0.05% to about 50% , from about 0.05% to about 25%, from about 0.05% to about 10%, from about 0.1% to about 50%, from about 0.1% to about 25%, from about 0.1% to about 10%, from about 1% to about 90%, from about 1% to about 75%, from about 1% to about 50%, from about 1% to about 10%, from about 10% to about 90%, from about 10% to about 75%, from about 10% to about 50%, or from about 10% to about 25% of the active ingredient, i.e., the lipoprotein.
- the dosage of the active ingredient depends upon the intended recipient (e.g. species), its age, weight, and indi vidual condition, and the administration route.
- An optimal dosage for a particular active ingredient and a particular target population can be determined by standard studies involving observation of appropriate immune responses in subjects.
- the lipoprotein or immunogenic composition provides protective immunity to a subject against a coronavirus. In certain embodiments, the lipoprotein or immunogenic composition decreases the severity of a coronavirus infection. In certain embodiments, the lipoprotein or immunogenic composition provides protective immunity to a subject against the coronavirus for at least about 1 month, about 2 months, about 3 months, about 4 months, about 5 months, about 6 months, about 9 months, about 12 months, about 18 months, about 2 years, about 3 years, about 4 years, about 5 years, or about 10 years after administration to the subject. In certain embodiments, the lipoprotein or immunogenic composition induces the production of antibodies against at least a portion of a coronavirus spike protein.
- a single dose of the lipoprotein or immunogenic composition induces an immune response in a subject sufficient to provide protective immunity to the subject against the coronavirus.
- a two doses of the lipoprotein or immunogenic composition induces an immune response in a subject sufficient to provide protective immunity to the subject against the coronavirus.
- the lipoprotein or immunogenic composition does not induce antibodydependent enhancement.
- the lipoprotein or immunogenic composition has an efficacy rate of greater than about 20%, greater than about 30%, greater than about 40%, greater than about 50%, greater than about 60%, greater than about 70%, greater than about 80%, or greater than about 90%. In certain embodiments, the lipoprotein or immunogenic composition has an reactogenicity rate of less than about 20%, less than about 15%, less than about 10%, less than about 8%, less than about 5%, less than about 3%, less than about 2%, or less than about 1%.
- contemplated herein is a method of immunizing a subject against a coronavirus comprising administering to the subject the lipoprotein or immunogenic composition disclosed herein.
- a method of of eliciting an immune response in a subject comprising administering to the subject an immunogenically effective amount of a lipoprotein comprising a coronavirus antigen described herein.
- provided herein is a method of preventing or reducing risk of a coronavirus infection in a subject comprising administering to the subject the lipopeptide or immunogenic composition disclosed herein. In certain embodiments, provided herein is a method of treating a coronavirus infection in a subject comprising administering to the subject the lipopeptide or immunogenic composition disclosed herein. In certain embodiments, provided herein is a method of reducing symptoms of a coronavirus infection in a subject comprising administering to the subject the lipopeptide or immunogenic composition disclosed herein.
- the immunogenic composition is administered by any enteral or parenteral routes, for example, by intranasal, oral, sublingual, intramuscular, intradermal, transdermal, subcutaneous, or transcutaneous routes.
- the lipoprotein or immunogenic composition is administered as a single dose. In certain embodiments, the lipoprotein or immunogenic composition is administered as two or more doses. In certain embodiments, the lipoprotein or immunogenic composition disclosed herein is administered as a booster vaccine, to boost preexisting immune responses in prior patients who have been previously infected with a coronavirus, or alternatively in heterologous prime-boost regimens with other coronavirus vaccines.
- the lipoprotein or immunogenic composition disclosed herein is administered in a heterologous prime-boost regimen in which a subject is administered a prime immunogenic composition and then later administered a booster immunogenic composition that is different from the first immunogenic composition.
- any aspect or component to the booster immunogenic composition can be different from the prime immunogenic composition, including, but not limited to, an antigen, adjuvant, excipient, lipopeptide, amphipathic domain, T-helper epitope, and the like.
- the booster immunogenic composition comprises an antigen that is heterologous to the prime immunogenic composition.
- the booster immunogenic composition comprises an adjuvant that is heterologous to the prime immunogenic composition.
- the booster immunogenic composition comprises an excipient that is heterologous to the prime immunogenic composition.
- the prime immunogenic composition comprises the lipoprotein disclosed herein and the boost immunogenic composition comprises a heterologous antigen.
- the boost immunogenic composition comprises the lipoprotein disclosed herein and the prime immunogenic composition comprises a heterologous antigen.
- the heterologous antigen can be another coronavirus antigen, such as a recombinant SARS-CoV-2 spike protein, messenger RNA- or DNA-encoding a corona virus antigen, which may be delivered by a non-replicating viral vector, virosome, liposome or a lipid nanoparticle, a killed inactivated coronavirus such as a P-propiolactone-treated coronavirus or a live attenuated coronavirus.
- a subject is administered the lipoprotein or immunogenic composition disclosed herein and subsequently administered a second immunogenic composition comprising a heterologous antigen.
- a subject is administered a first immunogenic composition comprising an antigen which is heterologous to antigens included in the lipoprotein or immunogenic composition disclosed herein, and subsequently the subject is administered the lipoprotein or immunogenic composition disclosed herein.
- the prime vaccine is selected from an inactivated coronavirus, a non-replicating viral vector coronavirus vaccine, a replicating viral vector coronavirus vaccine, a messenger RNA coronavirus vaccine, a DNA plasmid coronavirus vaccine, a coronavirus protein subunit vaccine, and a VLP coronavirus vaccine and the booster vaccine is a lipoprotein provided herein.
- the prime is a lipoprotein provided herein and the booster is selected from an inactivated coronavirus, a non-replicating viral vector coronavirus vaccine, a replicating viral vector coronavirus vaccine, a messenger RNA coronavirus vaccine, a DNA plasmid coronavirus vaccine, a coronavirus protein subunit vaccine, and a VLP coronavirus vaccine.
- the “booster” vaccine can be administered any time after the “prime” vaccine is administered, including, for example, 1 week, 2 weeks, 3 weeks, 4 weeks, 5 weeks, 6 weeks, 7 weeks, 8 weeks, 3 months, 4 months, 5 months, 6 months, 7 months, 8 months, 9 months, 10 months, 11 months, 12 months, 18 months, 2 years, 3 years, 4 years, or 5 years after administration of the “prime” vaccine.
- the subject is an animal. In certain embodiments, the subject is a warm-blooded mammal. In certain embodiments, the subject is a non-human primate. In certain embodiments, the subject is a human. In certain embodiments, the subject is immunocompromised. In certain embodiments, the subject is 60 years of age or older. In certain embodiments, the subject is a pediatric subject. In certain embodiments, the subject is under the age of 10. In certain embodiments, the subject is under the age of 6.
- lipoproteins disclosed herein are produced, depending on the composition, either by chemical synthesis using Fmoc solid phase peptide synthesis (SPPS) or by recombinant protein expression.
- SPPS Fmoc solid phase peptide synthesis
- the peptide chain is assembled stepwise on a solid support using Fmoc protected amino acids and standard solid phase peptide synthesis (SPPS) methods. Following assembly of the peptide and removal of the N-terminal protecting groups, the lipid is coupled to the N-terminus using standard solid phase peptide synthesis (SPPS) methods. Following assembly, the lipoprotein is cleaved and the sidechain protecting groups are removed by treatment with acid (TFA). The crude lipopeptide is then purified by high performance liquid chromatography (HPLC) using a reversed phase column. Disulfide bonds are formed either prior to cleavage by on-resin oxidation or in solution using suitable oxidizing agents (Chan, Weng C., and Peter D.
- SPPS solid phase peptide synthesis
- the lipoprotein is lyophilized or dissolved in a suitable storage buffer.
- the purity and identitiy are determined by HPLC and mass spectrometry (MS).
- a signal peptide sequence containing a charged N-terminal region, a hydrophobic region and a C-terminal lipobox (consensus sequence X1X2X3C, where Xi is selected from Leu, Vai, He, X2 is selected from Ala, Ser, Thr, Vai, He, and X3 is selected from Ala, Ser, Gly) is fused to the N-terminus of the target lipoprotein.
- the resulting amino acid sequence is converted into a DNA sequence with codon optimization for expression in E. coli (or another suitable host).
- the resulting DNA sequence is synthesized chemically, cloned into an expression vector, transformed into host cells, and transformed cells are grown in LB-, TB- or another suitable medium. Protein expression is induced by inoculation with isopropylthio-B-D-galactoside (IPTG) (or another suitable reagent). Cells are harvested, disrupted, pelleted and the lipoproteins are extracted using a buffer containing 1% Triton-X- 100 (or another suitable detergent). The crude lipoproteins are purified by chromatography using immobilized metal ion affinity chromatography (IMAC), ion exchange (IEX), size exclusion (SEC) and/or reversed phase HPLC columns.
- IMAC immobilized metal ion affinity chromatography
- IEX ion exchange
- SEC size exclusion
- the lipoprotein is folded in a refolding buffer.
- the lipoprotein is lyophilized or dialyzed into in a storage buffer. Purity and identitiy are determined by SDS-PAGE, Western Blot or HPLC and MS.
- the lipoproteins disclosed herein are tested for immunogenicity. Test subjects are immunized one or more times with the lipoproteins disclosed herein with or without coadministration of an exogenous adjuvant. Blood sera are analyzed by ELISA to determine titers of antibodies binding to the antigens disclosed herein, competition assay to determine antibodies inhibiting SARS-CoV-2 S binding to ACE-2 or SARS-CoV-2 neutralization assays to determine neutralizing antibodies.
- SARS-CoV-2 Antigen Antibody Assay Blood is collected before the first immunization and after each immunization, and the sera are analyzed by ELISA for antibodies binding to the SARS-CoV-2 antigens disclosed herein. All immunized subjects exhibit high titers of target antigen-specific (e.g. SARS-CoV-2 antigen) antibodies compared to unimmunized control subjects.
- target antigen-specific e.g. SARS-CoV-2 antigen
- SARS-CoV-2 Competition Assay Blood is collected before the first immunization and after the final immunization, and the sera are analyzed by competition ELISA or SPR for antibodies reducing binding of a recombinant SARS-CoV-2 S protein fragments to ACE-2. All immunized subjects exhibit antibodies that reduce binding of the recombinant SARS-CoV-2 S protein fragment compared to unimmunized control subjects.
- SARS-CoV-2 Pseudovirus Assay Blood is collected before the first immunization and after the final immunization, and the sera are analyzed by SARS-CoV-2 spike pseudotyped lentivirus neutralization assay for neutralizing antibodies. All immunized subjects exhibit high neutralization titers compared to unimmunized control subjects.
- SARS-CoV-2 Neutralization Assay Blood is collected before the first immunization and after the final immunization, and the sera are analyzed by SARS-CoV-2 neutralizing antibody assay for neutralizing antibodies against SARS-CoV-2. All immunized subjects exhibit high neutralization titers compared to unimmunized control subjects.
- SARS-CoV-2 Challenge and Viral Titrations Immunized test subjects are exposed to an infectious dose of SARS-CoV-2. The lungs are analyzed for virus by virus titration or RT-PCR and pulmonary inflammation by histopathology or RT-PCR (based on several parameters of lung inflammation that are converted to a pathology score). All immunized subjects exhibit high low lung virus titers, and low lung pathology score compared to SARS-CoV-2 exposed control subjects.
- Example 3 Safety and Efficacy Studies
- Subjects are immunized with any of the lipoproteins disclosed herein, including constructs comprising SARS-CoV-2 antigens.
- SARS-CoV-2 Reinfection Rates Immunized subjects who are naive to SARS- CoV-2 infection show lower infection rates as compared to control subjects. Immunized subjects who have previously been infected with SARS-CoV-2 show lower reinfection rates as compared to control subjects.
- Lipoprotein construct 1 comprises the lipid Cys((R)-2,3-di(palmitoyloxy)-2-propyl) (Pam2Cys), the artificially designed coiled-coil: lAALKQEIAALKKENAALKFEIAAL (SEQ-ID No: 5), the SARS- CoV-2 RBD antigen STEIYQAGSTPCNGVEGFNCYFPLQSWTG ⁇ D-Ala ⁇ (SEQ-ID No: 150) and a C-terminal carboxamide.
- Lipoprotein construct 1 was synthesized by SPPS on ChemMatrix Rink amide resin (loading 0.4 mmol/g) loading 0.4 mmol/g), using DIC/C1- HOBt for activation and 20% piperidine in DMF for Fmoc removal. After each coupling step, any remaining free amino groups were capped with acetic anhydride. ⁇ Pam2Cys ⁇ was coupled to the N-terminus using Fmoc-Cys((R)-2,3-di(palmitoyloxy)propyl-OH. The two other cysteines were coupled using Fmoc-Cys(Acm)-OH.
- the disulfide bond was obtained by on-resin oxidation for 1 hour using 15 eq. of iodine in DMF followed by washing with 1 M ascorbate-DMF (lx), DMF (4x) and CH2CI2 (2x).
- the resin was treated with TFA/TIPS/water 95:2.5:2.5 for 3 hours.
- the resin was filtered, the filtrate was precipitated and washed with cold ethyl ether, dried in vacuo, and the lipoprotein 1 was purified by reverse phase HPLC on a C4 column.
- SARS-CoV-2 S RBM Residues 438-506, SEQ ID NO: 104
- Imject alum adjuvant Thermo Fisher Scientific Inc., MA
- Blood sera collected on days 0 and 42 were analyzed for SARS-CoV-2 inhibiting antibodies using a commercial SARS-CoV-2 RBD/ACE-2 blocking ELISA kit (Cat. No L00847, GenScript USA, Inc., NJ). Inhibition rates were determined and calculated according to the manufacturer's protocol. Day 42 sera showed inhibition rates of 89%, 60% and 62%. Sera from confirmed COVID-19 patients showed inhibition rates of > 20%.
Abstract
Disclosed herein is a lipoprotein comprising (1) a lipopeptide building block comprising a lipid moiety and an amphipathic domain and (2) an antigen of a coronavirus, pharmaceutical compositions comprising the same, and methods of treating and preventing a coronavirus comprising administering to a subject the same.
Description
IMMUNOGENIC COMPOSITIONS FOR CORONAVIRUSES
CROSS-REFERENCE TO RELATED APPLICATIONS
[0001] This application claims the benefit of U.S. Provisional Application No. 63/113,107, filed November 12, 2020, the disclosure of which is incorporated by reference herein in its entirety.
SEQUENCE LISTING
[0002] This application incorporates by reference a Sequence Listing submitted with this application as a text file, entitled 14671-001-228_ST25.txt, created on November 8, 2021, and is 880,739 bytes in size.
BACKGROUND
[0003] Coronaviruses are species of viruses belonging to the subfamily Coronavirinae in the family Coronaviridae, and are positive-sense RNA viruses that infect humans and animals and cause respiratory, gastrointestinal or neurologic disease. Human coronavrisues include 229E, NL63, OC43, HKU1, MERS-CoV, SARS-CoV, and SARS-CoV-2. Common human coronaviruses include OC43, HKU1, 229E, and HCoV-NL63 that cause common colds and more severe lower respiratory tract infections in the very young and the elderly. Over the past two decades, three serious coronaviruses outbreaks have occurred, including SARS-CoV, MERS-CoV, and most recently, SARS-CoV-2 (also referred to as COVID-19), which resulted in a worldwide pandemic, infecting millions of people and causing substantial human death. There are currently no FDA-approved preventative or therapeutic vaccines for use against human coronaviruses and there is an urgent need for agents that can be used in methods for treating, preventing, or ameliorating coronaviruses, such as SARS-CoV-2, and diseases, disorders, and conditions related thereto.
[0004] Synthetic virus-like particles (SVLPs) have been utilized for vaccine development. Specifically, SVLP -based vaccine candidates using synthetic lipopeptide building blocks to which antigens are conjugated, which spontaneously self-assemble into immunogenic nanoparticles have been developed (see, WO2015/082501 and WO2020/127728). Additionally, certain SLVPs have been developed that include T-helper epitopes and coiled-coil domains (see, WO2018/229159 and W02008/068017). Despite these recent developments, there is still a need for SVLP -based vaccine candidates, most
particularly for treating, preventing, or ameliorating coronaviruses, such as SARS-CoV-2, and diseases, disorders, and conditions related thereto.
SUMMARY
[0005] In a first aspect, disclosed herein is a lipoprotein comprising (a) a lipopeptide building block comprising: (i) a lipid moiety and (ii) an amphipathic domain; and (b) an antigen of a coronavirus. In certain embodiments, the lipoprotein is a nanomicelle. In certain embodiments, the lipid moiety is a Toll-like receptor (TLR) agonist. In certain embodiments, the TLR agonist is a TLR-2 agonist. In certain embodiments, the lipid moiety has a structure selected from the group consisting of LM1, LM2, LM3, LM4, LM5, LM6, LM7, and LM8. In certain embodiments, the lipid moiety is selected from the group consisting of Cys((R)- 2,3-di(palmitoyloxy)-2-propyl) (Pam2Cys), Cys((R)-2,3-di(palmitoyloxy)-2-propyl-N- palmitoyl) (Pam3Cys), unsaturated Pam3Cys, phosphatidylethanolamine, diphosphoryl hexaacyl lipid A, l,2-dipalmitoyl-sn-glycero-3 -phosphoethanolamine, and 1,3-dipalmitoyl- glycero-2-phosphoethanolamine.
[0006] In certain embodiments, the amphipathic domain is a coiled-coil domain. In certain embodiments, the coiled-coil domain directs formation of helical bundles. In certain embodiments, the coiled-coil domain comprises a heptad motif, (abcdefg)n, wherein each a and d independently represents a hydrophobic residue and each b, c, e, f, and g independently represents a polar residue. In certain embodiments, the amphipathic domain comprises an amino acid sequence selected from the group consisting of SEQ ID Nos. 1-48. In certain embodiments, the amphipathic domain comprises an amino acid sequence consisting of an amino acid sequence selected from the group consisting of SEQ ID Nos. 1-48. In certain embodiments, the amphipathic domain consists of an amino acid sequence selected from the group consisting of SEQ ID Nos. 1-48.
[0007] In certain embodiments, the lipoprotein further comprises a T-helper epitope. In certain embodiments, the lipopeptide building block further comprises a T- helper epitope. In certain embodiments, the T- helper epitope is selected from the group consisting of a flu, hepatitis B, tetanus toxin, diphtheria toxin, and measles T-helper epitope. In certain embodiments, the T-helper epitope comprises an amino acid sequence selected from the group consisting of SEQ ID Nos. 49-77. In certain embodiments, the CD4+ T-helper cell epitope comprises an amino acid sequence selected from the group consisting of SEQ ID Nos. 49-77.
[0008] In certain embodiments, the coronavirus is a human coronavirus. In certain embodiments, the coronavirus is an alpha coronavirus. In certain embodiments, the coronavirus is a beta coronavirus. In certain embodiments, the coronavirus is selected from the group consisting of 229E, NL63, OC43, HKU1, MERS-CoV, SARS-CoV, and SARS- CoV-2. In certain embodiments, the coronavirus is SARS-CoV-2. In certain embodiments, the antigen comprises at least one of a B-cell epitope, CD4+ T-cell epitope, or CD8+ T-cell epitope. In certain embodiments, the antigen is a modified SARS-CoV-2 Spike protein epitope. In certain embodiments, the modified SARS-CoV-2 Spike protein epitope comprises at least one modification selected from the group consisting of a linker, a carboxamide, hairpin cap, a cysteine residue, and a furin cleavage site, a serin protease cleavage site, and an amino acid substitution.
[0009] In certain embodiments, the antigen comprises an amino acid sequence selected from the group consisting of SEQ ID Nos. 96-193. In certain embodiments, the antigen comprises an amino acid sequence consisting of an amino acid sequence selected from the group consisting of SEQ ID Nos. 96-193. In certain embodiments, the antigen consists of an amino acid sequence selected from the group consisting of SEQ ID Nos. 96-193.
[0010] In certain embodiments, the lipoprotein further comprises one or more linkers. In certain embodiments, the antigen is coupled to the lipopeptide building block via the one or more linkers. In certain embodiments, the amphipathic domain is coupled to the lipid moiety via the one or more linkers. In certain embodiments, the one or more linkers is a peptide linker.
[0011] In certain embodiments, the one or more linkers comprises an amino acid sequence selected from the group consisting of SEQ ID Nos. 194-232.
[0012] In certain embodiments, the lipoprotein further comprises a purification tag coupled to the antigen. In certain embodiments, the purification tag is removable by treatment with a protease.
[0013] In certain embodiments, the purification tag comprises an amino acid sequence selected from the group consisting of SEQ ID Nos. 233-242.
[0014] In another aspect, disclosed herein is a lipoprotein comprising: (a) lipopeptide building block comprising: (i) a lipid moiety, (ii) an amphipathic domain, and (iii) a T-helper cell epitope; and (b) an antigen of SARS-CoV-2 coupled to the lipopeptide building block. [0015] In a further aspect, disclosed herein is an immunogenic composition comprising the lipoprotein of any one of the preceding embodiments. In certain embodiments, the immunogenic composition further comprises an adjuvant. In certain embodiments, the
adjuvant is selected from the group consisting of aluminum, amorphous aluminum hydroxyphosphate sulfate (AAHS), aluminum hydroxide, aluminum phosphate, potassium aluminum sulfate (Alum), monophosphoryl lipid A (MPL), squalene, cytosine phosphoguanine, QS-21, microcrystalline tyrosine, MF59, mannide monooleate, GLA, SLA, E6020, resiquimod (R848), imidazoquinolines, imiquimod, 3M-052, 2',3'-cGAMP, 3', 3'- cGAMP, cGMP, cAMP, AMP, muramyl dipeptide, poly I:C, CpGand combinations thereof. [0016] In a further aspect, disclosed herein is a lipoprotein or an immunogenic composition of any one of the preceding embodiments, wherein the lipoprotein provides protective immunity to a subject against the coronavirus. In certain embodiments, the lipoprotein or immunogenic composition provides protective immunity to a subject against the coronavirus for at least about 1 month, about 2 months, about 3 months, about 4 months, about 5 months, about 6 months, about 9 months, about 12 months, about 18 months, about 2 years, about 3 years, about 4 years, about 5 years, or about 10 years after administration to the subject. In certain embodiments, the lipoprotein induces an immune response in a subject sufficient to provide protective immunity to the subject against the coronavirus. In certain embodiments, the lipoprotein or the immunogenic composition induces the production of antibodies against at least a portion of the coronavirus spike protein. In certain embodiments, a single dose of the lipoprotein induces an immune response in a subject sufficient to provide protective immunity to the subject against the coronavirus.
[0017] In certain embodiments, two doses of the lipoprotein induce an immune response in a subject sufficient to provide protective immunity to the subject against the coronavirus. In certain embodiments, the lipoprotein does not induce antibody-dependent enhancement. In certain embodiments, the lipoprotein has an efficacy rate of greater than about 20%, greater than about 30%, greater than about 40%, greater than about 50%, greater than about 60%, greater than about 70%, greater than about 80%, or greater than about 90%. In certain embodiments, the lipoprotein has an reactogenicity rate of less than about 20%, less than about 15%, less than about 10%, less than about 8%, less than about 5%, less than about 3%, less than about 2%, or less than about 1%.
[0018] In another aspect, disclosed herein is a method of immunizing a subject against a coronavirus comprising administering to the subject the lipoprotein or the immunogenic composition of any one of the preceding embodiments.
[0019] In yet another aspect, disclosed herein is a method of preventing or reducing risk of coronavirus infection in a subject comprising administering to the subject the lipoprotein or the immunogenic composition of any one of the preceding embodiments.
[0020] In a further aspect, disclosed herein is a method of treating a coronavirus infection in a subject comprising administering to a subject the lipoprotein or the immunogenic composition of any one of the preceding embodiments.
[0021] In yet a further aspect, disclosed herein is a method of reducing symptoms of a coronavirus infection in a subject comprising administering to the subject the lipoprotein or the immunogenic composition of any one of the preceding embodiments. In certain embodiments, the subject is human. In certain embodiments, the subject is immunocompromised. In certain embodiments, the subject is 60 years of age or older. In certain embodiments, the subject is a pediatric subject.
[0022] In another aspect, disclosed herein is a method of immunizing a subject against a coronavirus comprising: (a) administering to the subject a first immunogenic composition; and (b) administering to the subject a second immunogenic composition, the second immunogenic composition comprising a lipoprotein, the lipoprotein comprising (1) a lipopeptide building block and (2) a first antigen of a coronavirus, wherein the lipopeptide building block comprises lipid moiety and an amphipathic domain, and wherein the second immunogenic composition is heterologous to the first immunogenic composition; and wherein the second immunogenic composition is administered to the subject before or after the first immunogenic composition. In certain embodiments, the second immunogenic composition is administered to the subject before the lipoprotein. In certain embodiments, the second immunogenic composition is administered to the subject after the lipoprotein.
BRIEF DESCRIPTION OF THE DRAWINGS
[0023] FIG. 1 shows the structure of Construct No. 567 (in Table 6), specifically C- terminal structure of the peptide is depicted. SEQ ID NO:719.
[0024] FIG. 2 shows the structure of a lipoprotein construct having a Pam2Cys structure at the C-terminus.
[0025] FIG. 3 shows the structure of a lipoprotein construct having a Pam3Cys structure at the C-terminus.
[0026] FIG. 4 shows the structure of a lipoprotein construct having a Pam3Cys structure at the C-terminus.
[0027] FIG. 5 shows the structure of a lipoprotein construct having a Pam3Cys structure at the C-terminus.
DETAILED DESCRIPTION OF THE INVENTION
[0028] The present disclosure relates to a lipoprotein comprising (1) a lipopeptide building block (BB) (see, Section I herein) comprising a lipid moiety (LM) (see, Section I. A herein) and an amphipathic domain (AD) (see, Section I.B herein) and (2) an antigen of a coronavirus (A) (see Section II herein). In certain embodiments, the lipoprotein has the structure: BB-A, where BB represents the lipopeptide building block and A represents the antigen. In certain embodiments, the lipoprotein has the structure: LM-AD-A, where LM represents the lipid moiety, AD represents the amphipathic domain, and A represents the antigen. In certain embodiments, the lipopeptide building block and the antigen of a coronavirus are covalently linked, either directly or indirectly through a linker (L) (see, Section III herein). In certain embodiments, the lipoprotein has the structure: LM-L-AD-L-A. In certain embodiments, the lipopeptide building block further comprises a T-helper epitope (TH) (see, Section I.C herein), which can be linked, either directly or indirectly through a linker (L), to the amphipathic domain and the antigen. Accordingly, in certain embodiments, the lipoprotein has the structure LM-AD-TH-A, where wherein LM represents the lipid moiety, AD represents the amphipathic domain, TH represents the T-helper epitope, and A represents the antigen. In certain embodiments, each component of the lipoprotein can be either covalently linked to each other, either directly or indirectly through a linker (L). Accordingly, in certain embodiments, the lipoprotein has the structure LM-L-AD-L-TH-L-A, where each instance of linker (L) is optional. In certain embodiments, the lipoprotein construct can comprise the sequences set forth in Table 6 herein (see, Section IV herein). [0029] In certain embodiments, the lipoprotein is an immunogenic composition (see, Section V herein). In certain embodiments, disclosed herein are immunogenic compositions comprising the lipoprotein disclosed herein. In certain embodiments, the lipoprotein can be used to treat, prevent, or reduce the symptoms of a coronavirus infection (see, Section VI herein). In certain embodiments, the lipoprotein can be used as a coronavirus vaccine. In certain embodiments, the lipoprotein is a synthetic virus-like particle (SVLP). Without wishing to be bound by theory, it is thought that the disclosed lipoproteins which are SVLPs and thus exhibit a native virus-like shape can result in increased cross-reactivity and increased titers of functional antibodies, providing an advantage in utilizing the disclosed lipoproteins as vaccines. In certain embodiments, the lipoprotein is a nanomicelle.
I. Lipopeptide Building Block
[0030] In certain embodiments, the lipoprotein comprises a lipopeptide building block. In certain embodiments, the lipopeptide building block comprises a lipid moiety as disclosed in Section I. A herein and an amphipathic domain as disclosed in Section I.B herein. In certain embodiments, the lipopeptide building block further comprises a T-helper epitope as disclosed in Section I.C herein.
A. Lipid Moiety
[0031] In certain embodiments, the lipid moiety is a Toll-like receptor (TLR) agonist, for example, a TLR-1, TLR-2, TLR-4, TLR-5, TLR-6, or TLR- 10 agonist. In certain embodiments, the lipid moiety is a TLR-2 agonist.
[0032] In certain embodiments, the lipid moiety comprises hydrocarbyl chains. In certain embodiments, the lipid moiety comprises one or more hydrocarbyl chains. In certain embodiments, the lipid moiety comprises two hydrocarbyl chains. In certain embodiments, the lipid moiety comprises three hydrocarbyl chains. In certain embodiments, the lipid moiety is a phospholipid. The phospholipid can comprise either ester- or ether-linked extended alkyl or alkenyl side. In certain embodiments, the phospholipid comprises enantiomers of 1,2- dipalmitoyl-sn-glycero-3-phosphoethanolamine. In certain embodiments, the phospholipid comprises achiral analogues, including, but not limited to, l,3-dipalmitoyl-glycero-2- phosphoethanolamine.
[0034] wherein R1 and R^ in formulas LM 1 and LM 2 are independently of each other hydrocarbyl or hydrocarbyl-C=0, and Y is H orCOOH;
[0035]
LM 3
[0036] wherein Rl, R4 and R in formula LM 3 are independently of each other hydrocarbyl or hydrocarbyl-C=0; or Rl and R^ are independently of each other hydrocarbyl or hydrocarbyl-C=0 , and R is H or acetyl or lower alkyl-C=0;
[0037] wherein Rl and R^ in formulas LM 4 and LM 5 are independently of each other hydrocarbyl or hydrocarbyl-C=0 , and n is 1, 2, 3 or 4;
LM 6
[0038] wherein Rl and R^ in formula LM 6 are independently of each other a hydrocarbyl, X is
O or NH, and n is 1, 2, 3 or 4, or
[0039] wherein R1 and R^ in formulas LM 7 and LM 8 are independently of each other hydrocarbyl.
[0040] In certain embodiments, the lipid moiety is di-palmitoyl-S-glycerylcysteinyl of formula LM3, wherein R1 and R^ are palmitoyl, and R^ is H or acetyl.
[0041] In certain embodiments, the hydrocarbyl or hydrocarbyl chain is a straight or branched alkyl or alkenyl chain consisting of at least 7 carbon atoms, between 8 and 50 carbon atoms, between 8 and 25 carbon atoms, and optionally one, two or three double bonds. Alkenyl has one, two or three double bonds in the chain, each with E or Z geometry, as is customarily found in natural fatty acids and fatty alcohols. Also included in the definition of "hydrocarbyl" or "hydrocarbyl chain" is branched alkyl or alkenyl, for example alkyl bearing a methyl or ethyl substituent at the second or third carbon atom counted from the end of the chain, as e.g. as in 2-ethyl-hexyl. The term, "lower alkyl" means alkyl with 1 to 7 carbon atoms, including, for example, 1 to 4 carbon atoms, such as methyl, ethyl, n-propyl, iso-propyl, n-butyl, sec-butyl, iso-butyl or tert-butyl.
[0051] In certain embodiments, the lipid moiety is:
[0055] In certain embodiments, the lipid moiety is moiety is selected from the group consisting of Cys((R)-2,3-di(palmitoyloxy)-2-propyl) (also referred to as: Pam2Cys or dipalmitoyl-S-glyceryl cysteine), Cys((S)-2,3-di(palmitoyloxy)-2-propyl), Cys((R)-2,3- di(palmitoyloxy)-2-propyl-N-palmitoyl) (also referred to as: Pam3Cys or tripalmitoyl-S- glyceryl cysteine), unsaturated Pam3Cys, unsaturated Pam2Cys, N, N’ -dipalmitoyl. -2,3- diamino-propionamide (also referred to as: Pam2Dap), phosphatidylethanolamine, diphosphoryl hexaacyl lipid A, l,2-dipalmitoyl-sn-glycero-3 -phosphoethanolamine, and 1,3- dipalmitoyl-glycero-2-phosphoethanolamine. In certain embodiments, the lipid moiety comprises Pam2Cys. In certain embodiments, the lipid moiety consists of Pam2Cys. In certain embodiments, the lipid moiety comprises Pam3Cys. In certain embodiments, the lipid moiety consists of Pam3Cys.
B. Amphipathic Domain
[0056] The amphipathic domain can be a peptide chain comprising alternating hydrophobic residues (X) and hydrophilic residues (Y) with a general pattern of XmZnXoZp wherein m = 1-5, n = 1-5, o = 1-5, p = 0-5. In certain embodiments, the amphipathic domain has an amphipathic alpha helical structure with opposing polar and nonpolar faces oriented along the long axis of the helix. In certain embodiments, the amphipathic domain has amphipathic beta strand structure in which hydrophobic side-chains point in one direction and polar side-chains in the other. In certain embodiments, the amphipathic domain associates into a helical bundle. In certain embodiments, the amphipathic domain directs formation a coiled-coil. In certain embodiments, the amphipathic domain directs formation of an amphipathic beta sheet with at least two parallel beta strands in which hydrophobic side-chains point in one direction and polar side-chains in the other.
[0057] In certain embodiments, the amphipathic domain is a peptide structure comprising one chain. In certain embodiments, the amphipathic domain is a peptide structure comprising at least two chains. In certain embodiments, the amphipathic domain comprises parallel beta strands. In certain embodiments, the amphipathic domain comprises at least two peptide
chains are associated into a bundle. In certain embodiments, the at least two peptide chains each have an alpha helical secondary structure and are associated into a bundle. Accordingly, in certain embodiments, the amphipathic domain comprises, or consists of, a coiled-coil domain. In certain embodiments, the coiled-coil domain directs formation of helical bundles. Various amphipathic domains, including coiled-coil domains, that are suitable in certain embodiments disclosed herein are disclosed in WO 2008/068017, W02015/082501, WO 2018/229156, WO 2020/127728, WO 2009/109428, WO 2011/112999, US 9,044,514, US 9,994,646, US 7,811,577, US 8,728,785, each of which are herein incorporated by reference. [0058] In certain embodiments, the amphipathic domain comprises multiple repeat units consecutively linked to each other. The repeat units of the amphipathic domain segment may be identical or may be different, e.g. may contain at least one discontinuity, such as an insertion, deletion or exchange of at least one amino acid within the repeat unit. In certain embodiments, 1, 2, 3 or 4 amino acids within the repeat unit may be inserted, deleted, or exchanged.
[0059] In certain embodiments, the amphipathic domain comprises or consists of 2 to 10 repeat units including 2, 3, 4, 5, 6, 7, 8, 9 and 10 repeat units, 3 to 8 repeat units including 3, 4, 5, 6, 7, 8 repeat units, or 4 repeat units. Without wishing to be bound by theory, it is thought that an increase in the number of repeat units in the peptide moiety influences the stability of the domain. Accordingly, in certain embodiments, the amphipathic domain comprises at least two heptad repeats (e.g. two, three, four, five, six, seven, eight, nine, ten, or more, repeat units).
[0060] The amphipathic domain can be based on canonical repeat units and non- canonical repeat units. In certain embodiments, the amphipathic domain comprises canonical tandem heptad repeats that may form right-handed amphipathic alpha-helices, which then assemble to form helical bundles with left-handed coiled coils. In certain embodiments, the coiled-coil domain comprises non-canonical, non-heptad-based repeats that form coiled coils that are not necessarily left-handed or even regular supercoils.
[0061] Repeat units of amphipathic domains have a sequence with a certain number of amino acids, wherein the positions of the amino acids are labelled as lowercase letters. In a certain embodiments, the repeat unit of the coiled-coil domains consists of 7 to 15 amino acids or 7 to 11 amino acids. In certain embodiments, the coiled-coil domain comprises or consists of 7 amino acids, wherein the seven amino acid positions are designated with letters a, b, c, d, e, f and g. In a certain embodiments, the heptad motif includes amino acids having hydrophobic residues at positions a and d, and polar, helix- favoring residues at the other
residues. In certain embodiments, each of a and d can independently be selected from Ala, He, Leu, Met, Vai, Phe, Trp and Tyr. In certain embodiments, residues a and d can each independently be Gin or Asn. In certain embodiments, residues a and d each do not comprise N or Q. In certain embodiments, residues b, c, e, f and g are selected from Ala, Glu, Lys and Gin.
[0062] In certain embodiments, the amphipathic domain comprises or consists of 2 to 10 repeat units or 3 to 8 repeat units. In certain embodiments, the amphipathic domain comprises or consists of 4 repeat units. In certain embodiments, the amphipathic domain comprises or consists of 15, 11 or 7 amino acids. In certain embodiments, the amphipathic domain consists of 7 amino acids (heptad motif).
[0063] In certain embodiments, the amphipathic domain comprises 3-8 tandemly linked heptad motifs, wherein positions a and d in each heptad motif (abcdefg) contain alpha-amino acids belonging to the Group 1 and/or to the Group 2 as defined herein below. In certain embodiments, not more than two of all the a and d positions may be occupied by any amino acid residue belonging to the Group 3, and not more than one of all the a and d positions may be occupied by any amino acid residue belonging to the Group 4 or Group 5 or by glycine. In certain embodiments, positions b, c, e, f and g, are each independently selected from alphaamino acids belonging to the Groups 3, 4 and 5. In certain embodiments, at least one amino acid in positions b, c, e, f and g are hydrophobic. In certain embodiments, at least two amino acids in positions b, c, e, f and g are hydrophobic. In certain embodiments, at least three amino acids in positions b, c, e, f and g are hydrophobic. In certain embodiments, positions b, c, e, f and g, are each independently selected from a hydrophobic amino acid. In certain embodiments, positions b, c, e, f and g are each independently selected from amino acids belonging to the Groups 1 and 2.
[0064] Group 1 comprises alpha-amino acid residues with small to medium sized hydrophobic side chains. A hydrophobic residue refers to an amino acid side chain that is uncharged at physiological pH and that is repelled by aqueous solution. These side chains generally do not contain hydrogen bond donor groups, such as primary and secondary amides, primary and secondary amines and the corresponding protonated salts thereof, thiols, alcohols, ureas or thioureas. However, they may contain hydrogen bond acceptor groups such as ethers, thioethers, esters, tertiary amides, or tertiary amines. Genetically encoded amino acids in this group include alanine, isoleucine, leucine, methionine and valine.
[0065] Group 2 comprises amino acid residues with aromatic or heteroaromatic side chains. An aromatic amino acid residue refers to a hydrophobic amino acid having a side
chain containing at least one ring having a conjugated aromatic pi-electron system. In addition, it may contain additional hydrophobic groups such as lower alkyl, aryl or halogen, hydrogen bond donor groups such as primary and secondary amines, and the corresponding protonated salts thereof, primary and secondary amides, alcohols, and hydrogen bond acceptor groups such as ethers, thioethers, esters, tertiary amides or tertiary amines. Genetically encoded aromatic amino acids include phenylalanine and tyrosine. A heteroaromatic amino acid residue refers to a hydrophobic amino acid having a side chain containing at least one ring having a conjugated aromatic pi-system incorporating at least one heteroatom such as O, S and N . In addition such residues may contain hydrogen bond donor groups such as primary and secondary amides, primary and secondary amines and the corresponding protonated salts thereof, alcohols, and hydrogen bond acceptor groups such as ethers, thioethers, esters, tertiary amides or tertiary amines. Genetically encoded heteroaromatic amino acids include tryptophan and histidine.
[0066] Group 3 comprises amino acids containing side chains with polar non-charged residues. A polar non-charged residue refers to a hydrophilic side chain that is uncharged at physiological pH, but that is not repelled by aqueous solutions. Such side chains typically contain hydrogen bond donor groups such as primary and secondary amides, primary and secondary amines, thiols, and alcohols. These groups can form hydrogen bond networks with water molecules. In addition, they may also contain hydrogen bond acceptor groups such as ethers, thioethers, esters, tertiary amides, or tertiary amines. Genetically encoded polar noncharged amino acids include asparagine, cysteine, glutamine, serine and threonine. Non- proteinogenic polar amino acids include citrulline and homocysteine.
[0067] Group 4 comprises amino acids containing side chains with polar cationic residues and acylated derivatives thereof, such as acylamino-derived residues and urea-derived residues. Polar cationic side chains refer to a basic side chain, which is protonated at physiological pH. Genetically encoded polar cationic amino acids include arginine, lysine and histidine. Omitine is an example for a urea-derived amino acid residue.
[0068] Group 5 comprises amino acids containing side chains with polar anionic residues. Polar anionic refers to an acidic side chain, which is deprotonated at physiological pH. Genetically encoded polar anionic amino acids include aspartic acid and glutamic acid, for example, a polar anionic residue is -(CTLjaCOOH, wherein "a" is 1 to 4.
[0069] In certain embodiments, the amphipathic domain includes between 3 to 8 tandemly linked heptad motifs, wherein each heptad motif (abcdefg) may have any one of the following sequences: Ixxlxxx (referring respectively to the positions abcdefg); lxx2xxx
(referring respectively to the positions abcdefg); 2xxlxxx (referring respectively to the positions abcdefg); or 2xx2xxx (referring respectively to the positions abcdefg); wherein 1 is a genetically encoded amino acid from Group 1; 2 is a genetically encoded amino acid from Group 2; and wherein x is a genetically encoded amino acid from Groups 1, 2, 3, 4 or 5 or glycine. The alpha-amino acid with a hydrophobic side chain is selected from alanine, isoleucine, leucine, methionine and valine; the alpha-amino acid with aromatic or heteroaromatic residue is selected from phenylalanine, tyrosine, tryptophan and histidine; the alpha-amino acid with polar non- charged residue is selected from asparagine, cysteine, glutamine, serine and threonine; the alpha-amino acids with polar cationic residue is selected from arginine, lysine and histidine; and the alpha-amino acid with polar anionic residue is selected from aspartic acid and glutamic acid.
[0070] In certain embodiments, the amphipathic domain comprises or consists of amino acid sequences identified in naturally occurring peptides and proteins, but excluding those of human origin, for example, coiled-coil domains identified in viral and bacterial proteins. [0071] In certain embodiments, the amphipathic domain can be (XiX2X3X4XsX6X7)n (SEQ ID NO: 722), wherein Xi is a hydrophobic amino acid residue or asparagine, X2, X3, and Xe are each any amino acid residue, X4 is a hydrophobic amino acid residue, X5 and X7 are each a charged amino acid residue, and n is from 1 to 10. In certain embodiments, the amphipathic domain can be (lEKKIEXi)n (SEQ ID NO:723), wherein Xi is selected from A, G, T, and S, and n is 2. In certain embodiments, the coiled-coil domain includes E/K salt bridges between the b and f positions IEEKIKA/G/T/S (SEQ ID NO:724)and IECKIAA (SEQ ID NO:725). In certain embodiments, the amphipathic domain includes a cysteine residue for conjugation.
[0072] Exemplary amino acid sequences that can be included in the amphipathic domain are listed in Table 1 below, wherein Xi is selected from Vai, He, Leu, and Phe, X2 is selected from Glu, Lys, Arg, His, Ser, Thr, Asn, Gin, and Cys, X3 is selected from Glu, Lys, Arg, His, Ser, Thr, Asn, Gin, X4 is selected from He, Leu, Phe, X5 is selected from Glu, Lys and Gly, and Xe is selected from Ala, Gly, Lys, and any other hydrophilic amino acid, and variants thereof in which one, two, or three amino acids are replaced by other amino acids or are deleted.
[0073] Table 1. Amphipathic Domain Sequences.
[0074] In certain embodiments, the amphipathic domain comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 1-48
[0075] In certain embodiments, the amphipathic domain comprises an amino acid sequence consisting of an amino acid sequence selected from the group consisting of: SEQ ID NOs: 1-48.
[0076] In certain embodiments, the amphipathic domain consists of an amino acid sequence selected from the group consisting of SEQ ID NOs: 1-48.
C. T-helper Epitope
[0077] In certain embodiments, the lipopeptide building block further comprises a T- helper epitope. In certain embodiments, the T-helper epitope is selected from a flu, hepatitis B, tetanus toxin, diphtheria toxin, and measles T-helper epitope. In certain embodiments, the T-helper epitope is a flu T-helper epitope. In certain embodiments, the T-helper epitope is a tetanus toxin T-helper epitope. The T-helper epitopes that can be included in the lipopeptide building block are provided in Table 2 below, and variants thereof in which one, two, or three amino acids are replaced by other amino acids or are deleted.
[0079] In certain embodiments, the T-helper epitope comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 49-77.
[0080] In certain embodiments, the T-helper epitope comprises an amino acid sequence consisting of an amino acid sequence selected from the group consisting of: SEQ ID NOs: 49-77.
[0081] In certain embodiments, the T-helper epitope consists of an amino acid sequence selected from the group consisting of SEQ ID NOs: 49-77.
D. Signal Sequence
[0082] In certain embodiments, the lipopeptide building block comprises a signal sequence for cell-culture based expression of the lipopeptide building block. In certain embodiments, the signal sequence is fused to the N-terminus of the lipopeptide building block and then cleaved upon processing of the lipopeptide. Exemplary signal sequences that can be included in the lipopeptide building block are provided in Table 3 below:
[0084] In certain embodiments, the signal peptide is cleaved from the lipopeptide for use with the methods of treatment disclosed herein. In certain embodiments, the signal peptide comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 78-95.
[0085] In certain embodiments, the signal peptide comprises an amino acid sequence consisting of an amino acid sequence selected from the group consisting of: SEQ ID NOs: 78-95.
[0086] In certain embodiments, the signal peptide consists of an amino acid sequence selected from the group consisting of SEQ ID NOs: 78-95.
[0087]
II. Coronavirus Antigen
[0088] The lipoprotein can comprise a coronavirus antigen. In certain embodiments, the coronavirus antigen is conjugated directly or indirectly through a linker to a component of the
lipopeptide building block. In certain embodiments, the coronavirus antigen is connected, either directly or indirectly through a linker, through its N- or C-terminus, to the N- or to the C-terminal of the amphipathic domain, or to an amino acid side chain of the amphipathic domain. In certain embodiments, the coronavirus antigen is connected, either directly or indirectly through a linker, through its N- or C-terminus, to the N- or to the C-terminal of the T-helper epitope, or to an amino acid side chain of the T-helper epitope. In certain embodiments, the coronavirus antigen is connected to a component of the lipopeptide building block through a side chain residue of the coronavirus antigen, for example, through a terminal or internal aspartic acid, glutamic acid, lysine, ornithine or cysteine side chain. [0089] Without wishing to be bound by theory, it is thought that the disclosed antigens provide targeted responses to both linear and conformational epitopes and exclude of diseaseenhancing epitopes. In certain embodiments, the coronavirus antigen is a human coronavirus antigen. In certain embodiments, the coronavirus antigen is an alpha coronavirus antigen. In certain embodiments, the coronavirus antigen is a beta coronavirus antigen. In certain embodiments, the coronavirus antigen is selected from the group consisting of a 229E, NL63, OC43, HKU1, MERS-CoV, SARS-CoV, and SARS-CoV-2 antigen. In certain embodiments, the coronavirus antigen is a SARS-CoV-2 antigen. In certain embodiments, the antigen is selected from a B-cell epitope, CD4+ T-cell epitope, and CD8+ T-cell epitope. In certain embodiments, the antigen can comprise one or more of a B-cell epitope, CD4+ T-cell epitope, and CD8+ T-cell epitope. In certain embodiments, the antigen comprises a B-cell epitope. In certain embodiments, the antigen comprises a CD4+ T-cell epitope. In certain embodiments, the antigen comprises a CD8+ T-cell epitope. In certain embodiments, the antigen comprises a modified Spike protein epitope. In certain embodiments, the antigen comprises one or more epitopes from different coronaviruses. In certain embodiments, the antigen is a modified SARS-CoV-2 Spike protein epitope. In certain embodiments, the modified SARS-CoV-2 Spike protein epitope comprises at least one modification selected from the group consisting of a hairpin cap, a helix cap, a cysteine residue, a furin protease cleavage site, a serin protease cleavage site, a linker, a carboxamide, and an amino acid substitution. In certain embodiments, the amino acid substitution improves solubility. Accordingly, the amino acid substitution can be a hydrophilic amino acid. In certain embodiments, a hydrophobic amino acid may be substituted by a charged amino acid, such as Asp, Glu, Arg, Lys, ornitin (Orn), 1,3-diaminopropionic acid (Dap), or 1,4-diaminobutyric acid (Dab), 4-amino-proline (Amp). In certain embodiments, a hydrophobic amino acid may be substituted by a less hydrophobic amino acid such as Ala. In certain embodiments, the
amino substitution improves the stability. For example, in certain embodiments, a small hydrophobic amino acid can be substituted by a larger hydrophobic amino acid to fill an empty cavity inside the lipoprotein or an L-amino acid may be substituted by a D-amino acid to increase the stability towards proteases. Certain coronavirus antigen sequences that can be included in the disclosed lipoprotein are provided in Table 4 below, and variants thereof in which one, two, or three amino acids are replaced by other amino acids or are deleted. SEQ ID NOs: 63-70 are wild-type receptor binding domain peptides of the Spike protein SI subunit from SARS-CoV-2, SARS-CoV-1, HuCoV-229E, HuCoV-OC43, HuCoV-NL63, HuCoV-HKUl/BRA/22/2007, HuCoV-HKUl or MERS, respectively; SEQ ID NOs: 71-73 are wild-type receptor binding motif peptides from SARS-CoV-2, SARS-CoV-1 or MERS; SEQ ID NOs: 74-81 are wild-type Spike protein SI subunit SD1 peptides from SARS-CoV- 2, SARS-CoV-1, HuCoV-229E, HuCoV-OC43, HuCoV-NL63, HuCoV-
HKUl /BRA/22/2007, HuCoV-HKUl or MERS; SEQ ID NOs: 82-89 are wt Spike SD2 peptides from SARS-CoV-2, SARS-CoV-1, HuCoV-229E, HuCoV-OC43, HuCoV-NL63, HuCoV-HKUl/BRA/22/2007, HuCoV-HKUl or MERS; SEQ ID NOs: 90-96 are wild-type Spike protein S2 subunit FP peptides from SARS-CoV-2, SARS-CoV-1, HuCoV-229E, HuCoV-OC43, HuCoV-NL63, HuCoV-HKUl/BRA/22/2007 or MERS; SEQ ID NOs: 97- 103 are wild-type Spike protein S2 subunit HR1 peptide peptides from SARS-CoV-2, SARS- CoV-1, HuCoV-229E, HuCoV-OC43, HuCoV-NL63, HuCoV-HKUl/BRA/22/2007 or MERS; SEQ ID NOs: 104-110 are wild-type Spike protein S2 subunit HR2 peptide peptides from SARS-CoV-2, SARS-CoV-1, HuCoV-229E, HuCoV-OC43, HuCoV-NL63, HuCoV- HKUl /BRA/22/2007, HuCoV-HKUl or MERS; SEQ ID NOs: 111-160 are modified Spike protein SI or S2 subunit peptides from SARS-CoV-2, SARS-CoV-1, HuCoV-229E, HuCoV- OC43, HuCoV-NL63, HuCoV-HKUl /BRA/22/2007, HuCoV-HKUl or MERS.
[0091] In certain embodiments, the coronavirus antigen comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 96-193.
[0092] In certain embodiments, the coronavirus antigen comprises an amino acid sequence consisting of an amino acid sequence selected from the group consisting of: SEQ ID NOs: 96-193.
[0093] In certain embodiments, the coronavirus antigen consists of an amino acid sequence selected from the group consisting of SEQ ID NOs: 96-193.
[0094] In certain embodiments, the lipoprotein comprises a first coronavirus antigen and a second coronavirus antigen, wherein the first and second coronavirus antigens are connected via a linker, e.g., a peptide linker as disclosed herein. In certain embodiments, the N-terminus of the first coronavirus antigen is connected to the C-terminus of the second coronavirus antigen. In certain embodiments, the C-terminus of the first coronavirus antigen is connected to the N-terminus of the second coronavirus antigen.
III. Linkers
[0095] The components of the lipoprotein can be linked via various linkers. The linkers can include linkers having the structure LI to L16 below and/or short peptides of 2 to 20 amino acids (as discussed below). The amphipathic domain (AD) can be covalently linked to the lipid moiety (LM) at or near one terminus, i.e., the N-terminus or the C-terminus. In certain embodiments, the amphipathic domain is linked to the lipid moiety via the N-terminus of the amphipathic domain. In certain embodiments, the lipid moiety is directly linked to the amphipathic domain to form the structure: LM-AD. In certain embodiments, the lipid moiety is indirectly linked to the amphipathic domain via a linker to form the structure: LM-L-AD. Additionally, the coronavirus antigen can be linked to the lipopeptide building block (BB), for example, to the coiled-coil domain or to the T-helper epitope, via a linker, to form the structure BB-L-A.
[0096] If the components of the lipoprotein, for example, the amphipathic domain and the lipid moiety, or the coronavirus antigen and the BB, are directly linked, this can be accomplished, for example, through an amide bond between a lipid moiety carbonyl function and an amino function, e.g. the N-terminal amino function, of amphipathic domain. In certain embodiments, certain lipid moieties, e.g., LM1, LM2, and LM8 (as defined below), are connected through an amide bond between their amine function and a carboxy function, e.g., the C-terminal carboxy function, of the amphipathic domain.
[0097] A person of ordinary skill in the art would know that a wide variety of suitable linkers and coupling strategies exist, including, but not limited to, linkers based on dicarboxylic acid derivatives, linkers containing one or multiple ethylene glycol units, amino acid residues (including a-, P-, y-, 6-amino acids), or sugar (carbohydrate) units, or containing heterocyclic rings. In certain embodiments, the linker can have the structure of LI to L16 herein, wherein n is between 1 and 45 and m is between 1 and 45, for example wherein n is between 1 and 20 and m is between 1 and 20, shown with the connecting functional group C=0 and/or X wherein X is O or NH:
[0098] In certain embodiments, linkers LI to L16 may be connected to the lipid moiety and amphipathic domain as follows.
[0099] In certain embodiments, a carbonyl function shown for LI to L16 may be connected to an amino function of a suitable lipid moiety and/or an amino function, e.g. the N-terminal amino function, of the amphipathic domain through an amide bond. In certain embodiments, a carbonyl function shown for LI to LI 6 may be connected to a lipid moiety by replacement of the corresponding carbonyl function in particular lipid moieties LM3 to LM7.
[00100] In certain embodiments, a functional group X shown for LI to LI 6 (with the meaning -NH or -O) may be connected to a carbonyl function of a suitable lipid moiety and/or a carboxy function, e.g. the C-terminal carboxy function, of the amphipathic domain through an amide bond (for X = NH) or through an ester bond (for X = O).
[00101] In certain embodiments, the terminal -CH2 group of L8 may be connected to an amino function of a suitable lipid moiety, an amino function, e.g. the N-terminal amino
function, of the amphipathic domain, or a carbonyl function of a suitable lipid moiety. One of ordinary skill in the art would appreciate that the linker can be connected via a terminus of the amphipathic domain, or through a side chain residue of the amphipathic domain, for example, through such as a terminal or internal aspartic acid, glutamic acid, lysine, ornithine or cysteine side chain.
[00102] The coronavirus antigen can be conjugated directly or through a linker, either at the N- or C-terminus of the coronavirus antigen, and is connected either to the N- or to the C- terminal of the lipopeptide building block, or optionally to an amino acid side chain. Alternatively the coronavirus antigen can be conjugated to the lipopeptide building block through a side chain residue of the coronavirus antigen, such as a terminal or internal aspartic acid, glutamic acid, lysine, ornithine or cysteine side chain.
[00103] Suitable linkers for linking the coronavirus antigen to the lipopeptide building block include short peptides of 2 to 20 amino acids, hydroxyalkyl- or aminoalkyl-carboxylic acids, substituted or unsubstituted polyalkylenoxy glycols, e.g., containing one to twelve C2 and/or C3 alkylenoxy units, polyalkylenoxy glycol block co-polymers (e.g. pluronics), mono-, di-, tri- and oligosaccharides, which may comprise acetyl, glycerol-phosphate or other substituents at one or more positions, polysaccharides such as poly(sialylic acid) and derivatives (e.g. peptide conjugates) thereof, proteinogenic or non-proteinogenic amino acids, and Cl -C8 saturated or unsaturated hydrocarbons, and may comprise one or more of the following functional groups: a disulphide bond, amine, amide, acetal, ester, ether, thioether, hydrazone, hydrazide, imine, oxime, urea, thiourea, carbonate, iminocarbonate, amidine, amide, imide, an alkyl sue- cinimide, which may also be hydrolyzed to an amide, sulphonamide, sulfone, or a heterocyclic ring comprising one or more atoms selected from nitrogen and oxygen, for example a triazole, and combinations thereof. Any method used for conjugating peptides or other antigens to an antigen delivery system such as carrier protein, polymer, dendrimer, nanoparticle or virus-like particle, can be used to conjugate the coronavirus antigen to the lipopeptide building block component. Table 5 sets forth exemplary peptide linker sequences. In certain embodiments, the linker can have the sequence according to one of SEQ ID NOs: 194 to 230 herein, wherein z is any amino acid n is between 1 and 4 and m is between 1 and 4 and o is between 1 and 4 and x is between 1 and 20, and PEG is NH(CH2CH2O)xCH2CH2CO, with x = 1-20.
Table 5. Exemplary Peptide Linkers.
[00104] In certain embodiments, the peptide linker comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 194-232.
[00105] In certain embodiments, the peptide linker comprises an amino acid sequence consisting of an amino acid sequence selected from the group consisting of: SEQ ID NOs 194-232.
[00106] In certain embodiments, the peptide linker consists of an amino acid sequence selected from the group consisting of SEQ ID NOs: 194-232.
IV. Lipoprotein Constructs
[00107] In certain embodiments, the lipoprotein can have the structure set forth in Table 6, wherein Xi is selected from Leu, Vai, and He, X2 is selected from Ala, Ser, Thr, Vai, and He, and X3 is selected from Gly, Ala, and Ser, and PEG is NH(CH2CH2O)xCH2CE[2CO, with n = 1-20.
[00109] In certain embodiments, the lipoprotein comprises a structure selected from the group consisting of Constructs 1-573 as set forth in Table 6. In certain embodiments, the lipoprotein consists of a structure selected from the group consisting of Constructs 1-573 as set forth in Table 6. In certain embodiments, the lipoprotein comprises a structure as shown in Figures 1, 2, 3, 4, or 5. In certain embodiments, the lipoprotein comprises a structure as shown in Figure 1. In certain embodiments, the lipoprotein comprises a structure as shown in Figure 2. In certain embodiments, the lipoprotein comprises a structure as shown in Figure 3. In certain embodiments, the lipoprotein comprises a structure as shown in Figure 4. In certain embodiments, the lipoprotein comprises a structure as shown in Figure 5.
[00110] In certain embodiments, the lipoprotein constructs can comprise a purification tag coupled to the coronavirus antigen, for example, a hexa-His tag. In certain embodiments, the purification tag is directly coupled to the lipoprotein construct. In certain embodiments, the
purification tag is indirectly coupled to the lipoprotein construct via a linker. In certain embodiments, the purification tag is removable by treatment with a protease. In certain embodiments, the purification tag comprises one of the amino acid sequences set forth in Table 7.
[00112] In certain embodiments, the purification tag comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 233-242.
[00113] In certain embodiments, the purification tag comprises an amino acid sequence consisting of an amino acid sequence selected from the group consisting of SEQ ID NOs: 231-240.
[00114] In certain embodiments, the purification tag consists of an amino acid sequence selected from the group consisting of SEQ ID NOs: 233-242.
V. Immunogenic Pharmaceutical Compositions
[00115] In certain embodiments, the lipoprotein is an immunogenic composition. In certain embodiments, the lipoprotein is a vaccine, for example, a coronavirus vaccine. In certain embodiments, the immunogenic composition is a vaccine. In certain embodiments, the immunogenic composition comprises the lipoprotein disclosed herein, either alone or in combination with a pharmaceutically acceptable carrier. In certain embodiments, the immunogenic composition comprises one or more adjuvants selected from, for example, a mineral salt (e.g. aluminium hydroxide, aluminium phosphate, aluminium sulfate, calcium phosphate), monophosphoryl lipid A (MPL), plant extracts containing saponins (e.g. QS-21), imidazo-quinolines (e.g. Imiquimod), muramyl dipeptides and tripeptides, lipopeptides, oilin- water emulsions (e.g. Montanide ISA 720), cytokines (e.g. IL-2 or GM-CSF), mycobacterial and bacterial derivatives (e.g. Freund's complete adjuvant), BCG, nucleic acid derivatives (e.g. polylC) and other adjuvants known to those skilled in the art. In certain
embodiments, the adjuvant is selected from the group consisting of aluminum, amorphous aluminum hydroxyphosphate sulfate (AAHS), aluminum hydroxide, aluminum phosphate, potassium aluminum sulfate (Alum), monophosphoryl lipid A (MPL), squalene, cytosine phosphoguanine, QS-21, microcrystalline tyrosine, MF59, mannide monooleate, GLA, SLA, E6020, resiquimod (R848), imidazoquinolines, imiquimod, 3M-052, 2',3'-cGAMP, 3', 3'- cGAMP, cGMP, cAMP, AMP, muramyl dipeptide, poly I:C, CpG and combinations thereof. [00116] In certain embodiments, the immunogenic composition is encapsulated in or attached to bio-degradable polymers, which may for example be useful for controlled release, for example polylactic acid, poly-epsilon-caprolactone, polyhydroxybutyric acid, poly orthoesters, poly acetals, poly dihydropyrans, poly cyanoacrylates, and crosslinked or amphipathic block copolymers of hydrogels, or may be formulated in liposomes.
[00117] The immunogenic composition can be prepared according to conventional means known to a person of ordinary skill in the art, such as, for example, dissolving and lyophilizing processes and/or may comprise excipients, for example preservatives, stabilizers, wetting agents, tonicity adjusting agents and/or emulsifiers, solubilizers, salts for regulating osmotic pressure and/or buffering substances to stabilize the pH. including but not limited to sodium phosphate, potassium phosphate, sodium chloride, polysorbate 80, mannitol, sucrose, trehalose, amino acids such as glycine, histidine or the monosodium salt of glutamic acid and proteins such as human serum albumin.
[00118] In certain embodiments, the immunogenic composition comprises from about 0.05% to about 99%, from about 0.05% to about 75%, from about 0.05% to about 50% , from about 0.05% to about 25%, from about 0.05% to about 10%, from about 0.1% to about 50%, from about 0.1% to about 25%, from about 0.1% to about 10%, from about 1% to about 90%, from about 1% to about 75%, from about 1% to about 50%, from about 1% to about 10%, from about 10% to about 90%, from about 10% to about 75%, from about 10% to about 50%, or from about 10% to about 25% of the active ingredient, i.e., the lipoprotein.
[00119] As would be appreciated by a person of ordinary skill in the art, the dosage of the active ingredient depends upon the intended recipient (e.g. species), its age, weight, and indi vidual condition, and the administration route. An optimal dosage for a particular active ingredient and a particular target population can be determined by standard studies involving observation of appropriate immune responses in subjects.
[00120] In certain embodiments, the lipoprotein or immunogenic composition provides protective immunity to a subject against a coronavirus. In certain embodiments, the lipoprotein or immunogenic composition decreases the severity of a coronavirus infection. In
certain embodiments, the lipoprotein or immunogenic composition provides protective immunity to a subject against the coronavirus for at least about 1 month, about 2 months, about 3 months, about 4 months, about 5 months, about 6 months, about 9 months, about 12 months, about 18 months, about 2 years, about 3 years, about 4 years, about 5 years, or about 10 years after administration to the subject. In certain embodiments, the lipoprotein or immunogenic composition induces the production of antibodies against at least a portion of a coronavirus spike protein.
[00121] In certain embodiments, a single dose of the lipoprotein or immunogenic composition induces an immune response in a subject sufficient to provide protective immunity to the subject against the coronavirus. In certain embodiments, a two doses of the lipoprotein or immunogenic composition induces an immune response in a subject sufficient to provide protective immunity to the subject against the coronavirus. In certain embodiments, the lipoprotein or immunogenic composition does not induce antibodydependent enhancement.
[00122] In certain embodiments, the lipoprotein or immunogenic composition has an efficacy rate of greater than about 20%, greater than about 30%, greater than about 40%, greater than about 50%, greater than about 60%, greater than about 70%, greater than about 80%, or greater than about 90%. In certain embodiments, the lipoprotein or immunogenic composition has an reactogenicity rate of less than about 20%, less than about 15%, less than about 10%, less than about 8%, less than about 5%, less than about 3%, less than about 2%, or less than about 1%.
VI. Methods
[00123] In certain embodiments, contemplated herein is a method of immunizing a subject against a coronavirus comprising administering to the subject the lipoprotein or immunogenic composition disclosed herein. In certain embodiments, provided herein is a method of of eliciting an immune response in a subject comprising administering to the subject an immunogenically effective amount of a lipoprotein comprising a coronavirus antigen described herein.
[00124] In certain embodiments, provided herein is a method of preventing or reducing risk of a coronavirus infection in a subject comprising administering to the subject the lipopeptide or immunogenic composition disclosed herein. In certain embodiments, provided herein is a method of treating a coronavirus infection in a subject comprising administering to the subject the lipopeptide or immunogenic composition disclosed herein. In certain
embodiments, provided herein is a method of reducing symptoms of a coronavirus infection in a subject comprising administering to the subject the lipopeptide or immunogenic composition disclosed herein.
[00125] In certain embodiments, the immunogenic composition is administered by any enteral or parenteral routes, for example, by intranasal, oral, sublingual, intramuscular, intradermal, transdermal, subcutaneous, or transcutaneous routes.
[00126] In certain embodiments, the lipoprotein or immunogenic composition is administered as a single dose. In certain embodiments, the lipoprotein or immunogenic composition is administered as two or more doses. In certain embodiments, the lipoprotein or immunogenic composition disclosed herein is administered as a booster vaccine, to boost preexisting immune responses in prior patients who have been previously infected with a coronavirus, or alternatively in heterologous prime-boost regimens with other coronavirus vaccines.
A. Heterologous Prime-Boost Regimens
[00127] In certain embodiments, the lipoprotein or immunogenic composition disclosed herein is administered in a heterologous prime-boost regimen in which a subject is administered a prime immunogenic composition and then later administered a booster immunogenic composition that is different from the first immunogenic composition. In certain embodiments, any aspect or component to the booster immunogenic composition can be different from the prime immunogenic composition, including, but not limited to, an antigen, adjuvant, excipient, lipopeptide, amphipathic domain, T-helper epitope, and the like. In certain embodiments, the booster immunogenic composition comprises an antigen that is heterologous to the prime immunogenic composition. In certain embodiments, the booster immunogenic composition comprises an adjuvant that is heterologous to the prime immunogenic composition. In certain embodiments, the booster immunogenic composition comprises an excipient that is heterologous to the prime immunogenic composition. In certain embodiments, the prime immunogenic composition comprises the lipoprotein disclosed herein and the boost immunogenic composition comprises a heterologous antigen. In certain embodiments, the boost immunogenic composition comprises the lipoprotein disclosed herein and the prime immunogenic composition comprises a heterologous antigen. The heterologous antigen can be another coronavirus antigen, such as a recombinant SARS-CoV-2 spike protein, messenger RNA- or DNA-encoding a corona virus antigen, which may be delivered by a non-replicating viral vector, virosome, liposome or a lipid nanoparticle, a killed
inactivated coronavirus such as a P-propiolactone-treated coronavirus or a live attenuated coronavirus. In certain embodiments, a subject is administered the lipoprotein or immunogenic composition disclosed herein and subsequently administered a second immunogenic composition comprising a heterologous antigen. In certain embodiments, a subject is administered a first immunogenic composition comprising an antigen which is heterologous to antigens included in the lipoprotein or immunogenic composition disclosed herein, and subsequently the subject is administered the lipoprotein or immunogenic composition disclosed herein. In certain embodiments, the prime vaccine is selected from an inactivated coronavirus, a non-replicating viral vector coronavirus vaccine, a replicating viral vector coronavirus vaccine, a messenger RNA coronavirus vaccine, a DNA plasmid coronavirus vaccine, a coronavirus protein subunit vaccine, and a VLP coronavirus vaccine and the booster vaccine is a lipoprotein provided herein. In certain embodiments, the prime is a lipoprotein provided herein and the booster is selected from an inactivated coronavirus, a non-replicating viral vector coronavirus vaccine, a replicating viral vector coronavirus vaccine, a messenger RNA coronavirus vaccine, a DNA plasmid coronavirus vaccine, a coronavirus protein subunit vaccine, and a VLP coronavirus vaccine. The “booster” vaccine can be administered any time after the “prime” vaccine is administered, including, for example, 1 week, 2 weeks, 3 weeks, 4 weeks, 5 weeks, 6 weeks, 7 weeks, 8 weeks, 3 months, 4 months, 5 months, 6 months, 7 months, 8 months, 9 months, 10 months, 11 months, 12 months, 18 months, 2 years, 3 years, 4 years, or 5 years after administration of the “prime” vaccine.
[00128] In certain embodiments, the subject is an animal. In certain embodiments, the subject is a warm-blooded mammal. In certain embodiments, the subject is a non-human primate. In certain embodiments, the subject is a human. In certain embodiments, the subject is immunocompromised. In certain embodiments, the subject is 60 years of age or older. In certain embodiments, the subject is a pediatric subject. In certain embodiments, the subject is under the age of 10. In certain embodiments, the subject is under the age of 6.
[00129] It is to be understood that wherever values and ranges are provided herein, all values and ranges encompassed by these values and ranges, are meant to be encompassed within the scope of the present application. Moreover, all values that fall within these ranges, as well as the upper or lower limits of a range of values, are also contemplated by the present application.
[00130] The following examples further illustrate aspects of the present application.
However, they are in no way a limitation of the teachings or disclosure of the present application as set forth herein.
EXAMPLE
[00131] Example 1: Production of Lipoproteins
[00132] The lipoproteins disclosed herein are produced, depending on the composition, either by chemical synthesis using Fmoc solid phase peptide synthesis (SPPS) or by recombinant protein expression.
[00133] Chemical Synthesis. The peptide chain is assembled stepwise on a solid support using Fmoc protected amino acids and standard solid phase peptide synthesis (SPPS) methods. Following assembly of the peptide and removal of the N-terminal protecting groups, the lipid is coupled to the N-terminus using standard solid phase peptide synthesis (SPPS) methods. Following assembly, the lipoprotein is cleaved and the sidechain protecting groups are removed by treatment with acid (TFA). The crude lipopeptide is then purified by high performance liquid chromatography (HPLC) using a reversed phase column. Disulfide bonds are formed either prior to cleavage by on-resin oxidation or in solution using suitable oxidizing agents (Chan, Weng C., and Peter D. White. 2000. Fmoc solid phase peptide synthesis: a practical approach. New York: Oxford University Press.). For storage the lipoprotein is lyophilized or dissolved in a suitable storage buffer. The purity and identitiy are determined by HPLC and mass spectrometry (MS).
[00134] Expression: A signal peptide sequence containing a charged N-terminal region, a hydrophobic region and a C-terminal lipobox (consensus sequence X1X2X3C, where Xi is selected from Leu, Vai, He, X2 is selected from Ala, Ser, Thr, Vai, He, and X3 is selected from Ala, Ser, Gly) is fused to the N-terminus of the target lipoprotein. The resulting amino acid sequence is converted into a DNA sequence with codon optimization for expression in E. coli (or another suitable host). The resulting DNA sequence is synthesized chemically, cloned into an expression vector, transformed into host cells, and transformed cells are grown in LB-, TB- or another suitable medium. Protein expression is induced by inoculation with isopropylthio-B-D-galactoside (IPTG) (or another suitable reagent). Cells are harvested, disrupted, pelleted and the lipoproteins are extracted using a buffer containing 1% Triton-X- 100 (or another suitable detergent). The crude lipoproteins are purified by chromatography using immobilized metal ion affinity chromatography (IMAC), ion exchange (IEX), size exclusion (SEC) and/or reversed phase HPLC columns. The lipoprotein is folded in a
refolding buffer. For storage the lipoprotein is lyophilized or dialyzed into in a storage buffer. Purity and identitiy are determined by SDS-PAGE, Western Blot or HPLC and MS.
[00135] Example 2: Immunization Studies
[00136] The lipoproteins disclosed herein are tested for immunogenicity. Test subjects are immunized one or more times with the lipoproteins disclosed herein with or without coadministration of an exogenous adjuvant. Blood sera are analyzed by ELISA to determine titers of antibodies binding to the antigens disclosed herein, competition assay to determine antibodies inhibiting SARS-CoV-2 S binding to ACE-2 or SARS-CoV-2 neutralization assays to determine neutralizing antibodies.
[00137] SARS-CoV-2 Antigen Antibody Assay. Blood is collected before the first immunization and after each immunization, and the sera are analyzed by ELISA for antibodies binding to the SARS-CoV-2 antigens disclosed herein. All immunized subjects exhibit high titers of target antigen-specific (e.g. SARS-CoV-2 antigen) antibodies compared to unimmunized control subjects.
[00138] SARS-CoV-2 Competition Assay: Blood is collected before the first immunization and after the final immunization, and the sera are analyzed by competition ELISA or SPR for antibodies reducing binding of a recombinant SARS-CoV-2 S protein fragments to ACE-2. All immunized subjects exhibit antibodies that reduce binding of the recombinant SARS-CoV-2 S protein fragment compared to unimmunized control subjects.
[00139] SARS-CoV-2 Pseudovirus Assay. Blood is collected before the first immunization and after the final immunization, and the sera are analyzed by SARS-CoV-2 spike pseudotyped lentivirus neutralization assay for neutralizing antibodies. All immunized subjects exhibit high neutralization titers compared to unimmunized control subjects.
[00140] SARS-CoV-2 Neutralization Assay. Blood is collected before the first immunization and after the final immunization, and the sera are analyzed by SARS-CoV-2 neutralizing antibody assay for neutralizing antibodies against SARS-CoV-2. All immunized subjects exhibit high neutralization titers compared to unimmunized control subjects.
[00141] SARS-CoV-2 Challenge and Viral Titrations. Immunized test subjects are exposed to an infectious dose of SARS-CoV-2. The lungs are analyzed for virus by virus titration or RT-PCR and pulmonary inflammation by histopathology or RT-PCR (based on several parameters of lung inflammation that are converted to a pathology score). All immunized subjects exhibit high low lung virus titers, and low lung pathology score compared to SARS-CoV-2 exposed control subjects.
[00142] Example 3: Safety and Efficacy Studies
[00143] Subjects are immunized with any of the lipoproteins disclosed herein, including constructs comprising SARS-CoV-2 antigens.
[00144] SARS-CoV-2 Reinfection Rates. Immunized subjects who are naive to SARS- CoV-2 infection show lower infection rates as compared to control subjects. Immunized subjects who have previously been infected with SARS-CoV-2 show lower reinfection rates as compared to control subjects.
[00145] SARS-CoV-2 Safety and Efficacy. Immunized subjects show acceptable safety and efficacy against laboratory confirmed SARS-CoV-2 infection or reinfection.
[00146] Mild COVID-19 Efficacy and Reactogenicity Rates. Immunized subjects show efficacy rates of more than 20% against laboratory confirmed SARS-CoV-2 infection or reinfection with at least one of the following symptoms: difficulty of breathing, muscle or body aches, headache, loss of taste, loss of smell, sore throat, congestion, runny nose, nausea, vomiting, diarrhea. Immunized subjects show reactogenicity rates of less than 20%.
[00147] Severe COVID-19 Efficacy and Reactogenicity Rates. Immunized subjects show efficacy rates of more than 20% against laboratory confirmed severe SARS-CoV-2 infection or reinfection with any of the following: admission to the intensive care unit, respiratory failure, clinical signs of severe systemic illness, shock or death. Immunized subjects show reactogenicity rates of less than 20%.
[00148] Safety and Efficacy in Elderly, Immunocompromised, and Pediatric Populations. Subjects who are 60 years of age and older, pediatric subjects, and immunocompromised subjects are immunized. Immunized subjects show acceptable safety profiles and efficacy rates, are immunized with the lipoproteins disclosed herein, including Lipoproteins comprising SARS-CoV-2 antigens.
[00149] Example 4: Lipoprotein Constructs
[00150] Lipoprotein Construct 1
{Pam2Cys}GGEIAALKQEIAALKKENAALKFEIAALKQGPKYVKQNTLKLATKKKGG GGSTEIYQAGSTPCNGVEGFNCYFPLQSWTG{D-Ala}-NH2 (1) Lipoprotein construct 1 comprises the lipid Cys((R)-2,3-di(palmitoyloxy)-2-propyl) (Pam2Cys), the artificially designed coiled-coil: lAALKQEIAALKKENAALKFEIAAL (SEQ-ID No: 5), the SARS- CoV-2 RBD antigen STEIYQAGSTPCNGVEGFNCYFPLQSWTG{D-Ala} (SEQ-ID No: 150) and a C-terminal carboxamide. Lipoprotein construct 1 was synthesized by SPPS on ChemMatrix Rink amide resin (loading 0.4 mmol/g) loading 0.4 mmol/g), using DIC/C1- HOBt for activation and 20% piperidine in DMF for Fmoc removal. After each coupling step,
any remaining free amino groups were capped with acetic anhydride. {Pam2Cys} was coupled to the N-terminus using Fmoc-Cys((R)-2,3-di(palmitoyloxy)propyl-OH. The two other cysteines were coupled using Fmoc-Cys(Acm)-OH. The disulfide bond was obtained by on-resin oxidation for 1 hour using 15 eq. of iodine in DMF followed by washing with 1 M ascorbate-DMF (lx), DMF (4x) and CH2CI2 (2x). For cleavage the resin was treated with TFA/TIPS/water 95:2.5:2.5 for 3 hours. The resin was filtered, the filtrate was precipitated and washed with cold ethyl ether, dried in vacuo, and the lipoprotein 1 was purified by reverse phase HPLC on a C4 column. Analytical HPLC (4.6x250 mm KLM PS/DVB column, 15-55% acetonitrile/0.1% TFA in water/0.1% TFA in 25 min.): tR = 14.15 min. Purity: 92.2%. ESI-MS: MW calc, for C42H684N104O118S3: 9186.95; MW found = 9187.6 Da (± 0.01%). The induction of SARS-CoV-2 inhibiting antibodies was tested by immunizing three New Zealand White rabbits by intramuscular injection with 150pg lipoprotein 1 in 0.2 ml PBS without adjuvant on days 0 and 21. As control, three New Zealand White rabbits were immunized with SARS-CoV-2 S RBM (residues 438-506, SEQ ID NO: 104) (LifeTein, Inc. NJ) in Imject alum adjuvant (Thermo Fisher Scientific Inc., MA). Blood sera collected on days 0 and 42 were analyzed for SARS-CoV-2 inhibiting antibodies using a commercial SARS-CoV-2 RBD/ACE-2 blocking ELISA kit (Cat. No L00847, GenScript USA, Inc., NJ). Inhibition rates were determined and calculated according to the manufacturer's protocol. Day 42 sera showed inhibition rates of 89%, 60% and 62%. Sera from confirmed COVID-19 patients showed inhibition rates of > 20%. No inhibition could be detected in the sera from animals immunized with SARS-CoV-2 S RBM or pre-immune sera, indicating that immunization with lipoprotein construct 1 elicits high titers of SARS-CoV-2 inhibiting antibodies.
Claims
1. A lipoprotein comprising:
(a) a lipopeptide building block comprising: (i) a lipid moiety and (ii) an amphipathic domain; and
(b) an antigen of a coronavirus.
2. The lipoprotein of claim 1, wherein the lipoprotein is a nanomicelle.
3. The lipoprotein of any one of the preceding claims, wherein the lipid moiety is a Tolllike receptor (TLR) agonist.
4. The lipoprotein of claim 3, wherein the TLR agonist is a TLR-2 agonist.
5. The lipoprotein of any one of the preceding claims, wherein the lipid moiety has a structure selected from the group consisting of LM1, LM2, LM3, LM4, LM5, LM6, LM7, and LM8.
6. The lipoprotein of any one of the preceding claims, wherein the lipid moiety is selected from the group consisting of Cys((R)-2,3-di(palmitoyloxy)-2-propyl) (ParmCys), Cys((R)-2,3-di(palmitoyloxy)-2-propyl-N-palmitoyl) (ParmCys), unsaturated PamsCys, phosphatidyl ethanolamine, diphosphoryl hexaacyl lipid A, 1,2- dipalmitoyl-sn-glycero-3-phosphoethanolamine, and l,3-dipalmitoyl-glycero-2- phosphoethanolamine.
7. The lipoprotein of any one of the preceding claims, wherein the amphipathic domain is a coiled-coil domain.
8. The lipoprotein of claim 7, wherein the coiled-coil domain directs formation of helical bundles.
9. The lipoprotein of any one of claims 7-8, wherein the coiled-coil domain comprises a heptad motif, (abcdefg)n, wherein each a and d independently represents a hydrophobic residue and each b, c, e, f, and g independently represents a polar residue.
The lipoprotein of any one of the preceding claims, wherein the amphipathic domain comprises an amino acid sequence selected from the group consisting of SEQ ID Nos. 1-48. The lipoprotein of any one of the preceding claims, wherein the amphipathic domain comprises an amino acid sequence consisting of an amino acid sequence selected from the group consisting of SEQ ID Nos. 1-48. The lipoprotein of any one of the preceding claims, wherein the amphipathic domain consists of an amino acid sequence selected from the group consisting of SEQ ID Nos. 1-48. The lipoprotein of any one of the preceding claims, further comprising a T-helper epitope. The lipoprotein of any one of the preceding claims, wherein the lipopeptide building block further comprises a T- helper epitope. The lipoprotein of any one of claims 13 or 14, wherein the T- helper epitope is selected from the group consisting of a flu, hepatitis B, tetanus toxin, diphtheria toxin, and measles T-helper epitope. The lipoprotein of claim 15, wherein the T-helper epitope comprises an amino acid sequence selected from the group consisting of SEQ ID Nos. 49-77. The lipoprotein of claim 15, wherein the CD4+ T-helper cell epitope comprises an amino acid sequence selected from the group consisting of SEQ ID Nos. 49-77. The lipoprotein of any one of the preceding claims, wherein the coronavirus is a human coronavirus. The lipoprotein of any one of the preceding claims, wherein the coronavirus is an alpha coronavirus. The lipoprotein of any one of the preceding claims, wherein the coronavirus is a beta coronavirus.
The lipoprotein of any one of the preceding claims, wherein the coronavirus is selected from the group consisting of 229E, NL63, OC43, HKU1, MERS-CoV, SARS-CoV, and SARS-CoV-2. The lipoprotein of any one of the preceding claims, wherein the coronavirus is SARS- CoV-2. The lipoprotein of any one of the preceding claims, wherein the antigen comprises at least one of a B-cell epitope, CD4+ T-cell epitope, or CD8+ T-cell epitope. The lipoprotein of any one of the preceding claims, wherein the antigen is a modified SARS-CoV-2 Spike protein epitope. The lipoprotein of any one of the preceding claims, wherein the modified SARS- CoV-2 Spike protein epitope comprises at least one modification selected from the group consisting of a linker, a carboxamide, hairpin cap, a cysteine residue, a furin cleavage site, a serin protease cleavage site, and an amino acid substitution. The lipoprotein of any one of the preceding claims, wherein the antigen comprises an amino acid sequence selected from the group consisting of SEQ ID Nos. 96-193. The lipoprotein of any one of the preceding claims, wherein the antigen comprises an amino acid sequence consisting of an amino acid sequence selected from the group consisting of SEQ ID Nos. 96-193. The lipoprotein of any one of the preceding claims, wherein the antigen consists of an amino acid sequence selected from the group consisting of SEQ ID Nos. 96-193. The lipoprotein of any one of the preceding claims, further comprising one or more linkers. The lipoprotein of claim 29, wherein the antigen is coupled to the lipopeptide building block via the one or more linkers. The lipoprotein of any one of the preceding claims, wherein the amphipathic domain is coupled to the lipid moiety via the one or more linkers. The lipoprotein of claim 31, wherein the one or more linkers is a peptide linker.
The lipoprotein of claim 32, wherein the one or more linkers comprises an amino acid sequence selected from the group consisting of SEQ ID Nos. 194-232. The lipoprotein of claim any one of the preceding claims, further comprising a purification tag coupled to the antigen. The lipoprotein of claim 34, wherein the purification tag is removable by treatment with a protease. The lipoprotein of claim 35, where in the purification tag comprises an amino acid sequence selected from the group consisting of SEQ ID Nos. 233-242 . A lipoprotein comprising:
(a) a lipopeptide building block comprising: (i) a lipid moiety, (ii) an amphipathic domain, and (iii) a T-helper cell epitope; and
(b) an antigen of SARS-CoV-2 coupled to the lipopeptide building block. An immunogenic composition comprising the lipoprotein of any one of the preceding claims. The immunogenic composition of claim 38, further comprising an adjuvant. The immunogenic composition of claim 39, wherein the adjuvant is selected from the group consisting of aluminum, amorphous aluminum hydroxyphosphate sulfate (AAHS), aluminum hydroxide, aluminum phosphate, potassium aluminum sulfate (Alum), monophosphoryl lipid A (MPL), squalene, cytosine phosphoguanine, QS-21, microcrystalline tyrosine, MF59, mannide monooleate, GLA, SLA, E6020, resiquimod (R848), imidazoquinolines, imiquimod, 3M-052, 2',3'-cGAMP, 3', 3'- cGAMP, cGMP, cAMP, AMP, muramyl dipeptide, poly I:C, CpGand combinations thereof. The lipoprotein or the immunogenic composition of any one of the preceding claims, wherein the lipoprotein provides protective immunity to a subject against the coronavirus.
The lipoprotein or the immunogenic composition of any one of the preceding claims, wherein the lipoprotein provides protective immunity to a subject against the coronavirus for at least about 1 month, about 2 months, about 3 months, about 4 months, about 5 months, about 6 months, about 9 months, about 12 months, about 18 months, about 2 years, about 3 years, about 4 years, about 5 years, or about 10 years after administration to the subject. The lipoprotein of claim 1, wherein the lipoprotein induces an immune response in a subject sufficient to provide protective immunity to the subject against the coronavirus. The lipoprotein or the immunogenic composition of any one of the preceding claims, wherein the lipoprotein induces the production of antibodies against at least a portion of the coronavirus spike protein. The lipoprotein or the immunogenic composition of any one of the preceding claims, wherein a single dose of the lipoprotein induces an immune response in a subject sufficient to provide protective immunity to the subject against the coronavirus. The lipoprotein or the immunogenic composition of any one of the preceding claims, wherein two doses of the lipoprotein induce an immune response in a subject sufficient to provide protective immunity to the subject against the coronavirus. The lipoprotein or the immunogenic composition of any one of the preceding claims, wherein the lipoprotein does not induce antibody-dependent enhancement. The lipoprotein or the immunogenic composition of any one of the preceding claims, wherein the lipoprotein has an efficacy rate of greater than about 20%, greater than about 30%, greater than about 40%, greater than about 50%, greater than about 60%, greater than about 70%, greater than about 80%, or greater than about 90%. The lipoprotein or the immunogenic composition of any one of the preceding claims, wherein the lipoprotein has an reactogenicity rate of less than about 20%, less than about 15%, less than about 10%, less than about 8%, less than about 5%, less than about 3%, less than about 2%, or less than about 1%.
A method of immunizing a subject against a coronavirus comprising administering to the subject the lipoprotein or the immunogenic composition of any one of the preceding claims. A method of preventing or reducing risk of coronavirus infection in a subject comprising administering to the subject the lipoprotein or the immunogenic composition of any one of the preceding claims. A method of treating a coronavirus infection in a subject comprising administering to a subject the lipoprotein or the immunogenic composition of any one of the preceding claims. A method of reducing symptoms of a coronavirus infection in a subject comprising administering to the subject the lipoprotein or the immunogenic composition of any one of the preceding claims. The method of any one of claims 50-53, wherein the subject is human. The method of any of claims 50-54, wherein the subject is immunocompromised. The method of any one of claims 50-55, wherein the subject is 60 years of age or older. The method of any one of claims 50-55, wherein the subject is a pediatric subject. A method of immunizing a subject against a coronavirus comprising:
(a) administering to the subject a first immunogenic composition; and
(b) administering to the subject a second immunogenic composition, the second immunogenic composition comprising a lipoprotein, the lipoprotein comprising (1) a lipopeptide building block and (2) a first antigen of a coronavirus, wherein the lipopeptide building block comprises lipid moiety and an amphipathic domain, and wherein the second immunogenic composition is heterologous to the first immunogenic composition; and wherein the second immunogenic composition is administered to the subject before or after the first immunogenic composition.
The method of claim 57, wherein the second immunogenic composition is administered to the subject before the lipoprotein. The method of claim 57, wherein the second immunogenic composition is administered to the subject after the lipoprotein.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US202063113107P | 2020-11-12 | 2020-11-12 | |
US63/113,107 | 2020-11-12 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2022103927A1 true WO2022103927A1 (en) | 2022-05-19 |
Family
ID=81601666
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2021/058920 WO2022103927A1 (en) | 2020-11-12 | 2021-11-11 | Immunogenic compositions for coronaviruses |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2022103927A1 (en) |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20100015173A1 (en) * | 2006-12-09 | 2010-01-21 | Universität Zórich Prorektorat Forschung | Coiled-coil lipopeptide helical bundles and synthetic virus-like particles |
US20110250237A1 (en) * | 2008-07-15 | 2011-10-13 | O'hagan Derek | Immunogenic amphipathic peptide compositions |
US20140242152A1 (en) * | 2011-07-06 | 2014-08-28 | Andrew Geall | Immunogenic compositions and uses thereof |
WO2020127728A1 (en) * | 2018-12-20 | 2020-06-25 | Virometix Ag | Lipopeptide building blocks and synthetic virus-like particles |
-
2021
- 2021-11-11 WO PCT/US2021/058920 patent/WO2022103927A1/en active Application Filing
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20100015173A1 (en) * | 2006-12-09 | 2010-01-21 | Universität Zórich Prorektorat Forschung | Coiled-coil lipopeptide helical bundles and synthetic virus-like particles |
US20110250237A1 (en) * | 2008-07-15 | 2011-10-13 | O'hagan Derek | Immunogenic amphipathic peptide compositions |
US20140242152A1 (en) * | 2011-07-06 | 2014-08-28 | Andrew Geall | Immunogenic compositions and uses thereof |
WO2020127728A1 (en) * | 2018-12-20 | 2020-06-25 | Virometix Ag | Lipopeptide building blocks and synthetic virus-like particles |
Non-Patent Citations (3)
Title |
---|
MANNA ET AL.: "Probiotics-Derived Peptides and Their Immunomodulatory Molecules Can Play a Preventive Role Against Viral Diseases Including COVID-19", PROBIOTICS AND ANTIMICROBIAL PROTEINS, vol. 13, 23 November 2020 (2020-11-23), pages 611 - 623, XP037480527, DOI: 10.1007/s12602-020-09727-7 * |
SAFAVI ET AL.: "Exploring the out of sight antigens of SARS-CoV-2 to design a candidate multi-epitope vaccine by utilizing immunoinformatics approaches", VACCINE, vol. 38, 9 October 2020 (2020-10-09), pages 7612 - 7628, XP086320940, DOI: 10.1016/j.vaccine.2020.10.016 * |
WU ET AL.: "Vaccines and Therapies in Development for SARS-CoV-2 Infections", JOURNAL OF CLINICAL MEDICINE, vol. 9, no. 6, 16 June 2020 (2020-06-16), pages 1 - 19, XP055943754 * |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ES2719406T3 (en) | RSV recombinant antigens | |
JP6062245B2 (en) | Recombinant RSV antigen | |
AU2011305061B2 (en) | Novel immunostimulatory method | |
US9943583B2 (en) | Proline-rich peptides protective against S. pneumoniae | |
JP7356911B2 (en) | Cyclic peptide for prophylaxis against respiratory syncytial virus | |
WO2022103927A1 (en) | Immunogenic compositions for coronaviruses | |
CN113260377A (en) | Lipopeptide building blocks and synthetic virus-like particles | |
WO2009026353A1 (en) | Immunogen presenting hiv gp120 v3 loop in a conformation that induces broadly neutralizing antibodies | |
US20090104220A1 (en) | Method to Make a Peptide-Carrier Conjugate with a High Immunogenicity | |
US20040047867A1 (en) | Adjuvant composition comprising FHA protein or a fragment of FHA protein in its free form | |
WO1994006468A1 (en) | Recombinant influenza virus vaccine compositions | |
US20230109142A1 (en) | Corona virus vaccine | |
CA3213972A1 (en) | Compositions and methods for preventing rsv and piv3 infections | |
WO2021260176A1 (en) | Synthetic epitopes of betacoronaviruses |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 21892787 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 21892787 Country of ref document: EP Kind code of ref document: A1 |